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7ABSTRACT
Aims: Helicobacter pylori infection, although the prevalence is declining in Western
world, is still responsible for several clinically important diseases. None of the
diagnostic tests is perfect and in this study, the performance of three stool antigen
tests was assessed. In areas of high H. pylori prevalence,  the  definition  of  patients
with the greatest benefit from eradication therapy may be a problem; the role of
duodenal gastric metaplasia in categorizing patients at risk for duodenal ulcer was
evaluated in this respect. Whether persistent chronic inflammation and elevated H.
pylori antibodies after successful eradication are associated with each other or with
atrophic gastritis, a long term sequelae of H. pylori infection, were also studied.
Patients and methods: The three stool antigen tests were assessed in pre- and post-
eradication settings among 364 subjects in two studies as compared to the rapid
urease test (RUT), histology, culture, the 13C-urea breath test (UBT) and enzyme
immunoassay (EIA) based H. pylori serology. The association between duodenal
gastric metaplasia with duodenal ulcer was evaluated in a retrospective study
including 1054 patients gastroscopied due to clinical indications and 154 patients
previously operated for duodenal ulcer. The extent of duodenal gastric metaplasia was
assessed from histological specimens in different patient groups formed on the basis
of gastroscopy findings and H. pylori infection. Chronic gastric inflammation (108
patients) and H. pylori antibodies and serum markers for atrophy (77 patients) were
assessed in patients earlier treated for H. pylori.
Results: Of the stool antigen tests studied, the monoclonal antibody-based EIA-test
showed the highest sensitivity and specificity both in the pre-treatment setting (96.9%
and 95.9%) and after therapy (96.9% and 97.8%). The polyclonal stool antigen test
and the in-office test had at baseline a sensitivity of 91% and 94%, and a specificity of
96% and 89%, respectively and in a post-treatment setting, a sensitivity of 78% and
91%, and a specificity of 97%, respectively. Duodenal gastric metaplasia was strongly
associated with H. pylori positive duodenal ulcer (odds ratio 42). Although common
still five years after eradication, persistent chronic gastric inflammation (21%) and
8elevated H. pylori antibodies (33%) were neither associated with each other nor with
atrophic gastritis.
Conclusions: Current H. pylori infection can feasibly be diagnosed by a monoclonal
antibody-based EIA test with the accuracy comparable to that of reference methods.
The  performance  of  the  polyclonal  test  as  compared  to  the  monoclonal  test  was
inferior  especially  in  the  post-treatment  setting.  The  in-office  test  had  a  low
specificity for primary diagnosis and hence positive test results should probably be
confirmed with another test before eradication therapy is prescribed. The presence of
widespread duodenal gastric metaplasia showed promising results in detecting
patients who should be treated for H. pylori due to an increased risk of duodenal
ulcer. If serology is used later on in patients with earlier successfully treated for H.
pylori, it should be taken into account that H. pylori antibodies may persist elevated
for years for unknown reason. However, this phenomenon was not found to be
associated with persistent chronic inflammation or atrophic changes.
9INTRODUCTION
Since the discovery of Helicobacter pylori (H. pylori) in 1982 (Warren and Marshall,
1983) the associated diseases and the benefits of eradication therapy in many of them
have been clarified. Recently, updated guidelines on several topics concerning the
treatment indications and diagnosis have been published by the European
Helicobacter Pylori Study Group as Maastricht III Consensus Report (Malfertheiner et
al., 2007).
There are several methods available for the diagnosis of H. pylori infection, but none
of them is ideal and therefore, in many clinical situations several tests are needed.
Most of the tests originally developed for the diagnosis of H. pylori infection in
patients with peptic ulcer disease are now used in different settings: peptic ulcer
prevalence is rapidly declining and the prevention of gastric cancer at the
precancerous stage has become relatively more important. Also, the prevalence of H.
pylori infection is diminishing (Rehnberg-Laiho et al., 2001) and this has a great
impact even on the performance of those tests with high sensitivity and specificity.
Gastroscopy has become a commonplace diagnostic investigation in western countries
but at the same time the waiting list for this procedure has not necessarily shortened.
On the other hand, the increasing use of proton pump inhibitors (PPIs), although
efficiently alleviating abdominal symptoms hamper the endoscopic appearance and H.
pylori diagnosis (Mégraud and Lehours, 2007). In areas with high H. pylori
prevalence, the indications for eradication therapy must be allocated to patients with
the greatest benefit, one such group being patients with duodenal ulcer. It is easy to
detect an acute ulcer during gastroscopy, however, in patients with ulcer diathesis on
PPI therapy the scars in the duodenal bulb might be minimal and the diagnosis may be
overlooked. Clinically useful tools to identify patients at risk for duodenal ulcer are
needed.
In a subgroup of patients after H. pylori eradication therapy, chronic inflammation of
the gastric mucosa as well as elevated H. pylori antibodies prevail for long periods.
The mechanism behind these phenomena is obscure as is their possible association
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with each other or with clinical consequences e.g. atrophic gastritis, autoimmune
phenomena induced by H. pylori, or even gastric cancer risk.
Although the past 25 years of the H. pylori era have dramatically changed our
understanding and treatment of several gastric diseases, many questions still remain
open and need to be answered.
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REVIEW OF THE LITERATURE
HISTORY OF H. PYLORI
Spiral bacteria in gastric scrapings from dogs were described as early as in 1892 by
Bizzozero at a meeting in Turin (Bizzozero, 1893, Egan and O'Morain, 2007). The
first human report published was by Krienitz from a patient with gastric cancer in
1906 (Krienitz, 1906) and at that time spiral bacteria were also considered in the
development of gastric and duodenal ulceration, sometimes patients were even treated
with high doses of bismuth (Kusters et al., 2006). However, it was also suggested that
those  bacteria  were  only  contaminants  from  the  oral  cavity  (Egan  and  O'Morain,
2007). The modern era began when H. pylori was cultivated from gastric mucosa and
it’s association with gastritis and later with peptic ulcer was demonstrated by Warren
and Marshall, who were awarded with the Nobel Prize in Medicine 2005 (Warren and
Marshall, 1983, Marshall and Warren, 1984).
BACTERIOLOGY AND EPIDEMIOLOGY OF H. PYLORI
1. Bacteriology
Helicobacter and Wolinella comprise the family Helicobacteraceae which in turn
together with Campylobacteraceae belong to the Epsilonproteobacteria, class nov.
(Mégraud and Lehours, 2007). Thirty different Helicobacter species have been
formally named with a growing list of species waiting for formal recognition (List of
Prokaryotic Names with Standing in Nomenclature (http://www.bacterio.cict.fr)
Accessed 18th May 2007).
H. pylori is a Gram negative spiral shaped multi-flagellated bacteria found
almost exclusively on human gastric mucosa. Under unfavourable circumstances it
can become coccoidal, a nonculturable form with debatable viability. The bacterium
is a microaerophilic and capnophilic organism, slowly growing with rigorous culture
demands (Mégraud and Lehours, 2007). The phenotypic identification is based on the
growth of small, circular, smooth colonies observed after 3 to 4 days on selective
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media plated with gastric biopsy specimens. The identification of the cultured bacteria
is based on positive reactions for oxidase, catalase, and urease. So far, the complete
genomes of three H. pylori strains have been published (Tomb et al., 1997, Alm et al.,
1999, Oh et al., 2006b, Josenhans et al., 2007). H. pylori is genetically very
heterogenous (Kusters et al., 2006), and this genetic diversity of different H. pylori
strains was even exploited in a study suggesting that humans harboured H. pylori as
early as 58,000 years ago before migrations from Africa (Linz et al., 2007).
1.1. Virulence factors
Several virulence factors of H. pylori have been identified. The most studied is CagA,
which according to numerous studies, is associated with peptic ulcers, precancerous
conditions and gastric cancer in the Western world (Kusters et al., 2006). CagA
protein is a highly immunogenic protein encoded by the cagA gene, present in
approximately 50 to 70% of H. pylori strains.  It  is  a  marker  for  the  presence  of  a
genomic pathogenicity island PAI, encoding 27 to 31 proteins, 18 of which serve as
building blocks of the type IV secretory apparatus, fundamental in the aberration of
host immune responses (Odenbreit et al., 2000, Kusters et al., 2006, Robinson et al.,
2007). Another well-known virulence factor, cytotoxin VacA is associated with peptic
ulcer and adenocarcinoma. It is encoded by the gene vacA which is present in all
strains, but because of several alleles various amounts of toxin are produced and
approximately 50% of H. pylori strains  secrete  the  toxin  VacA.  The  most  virulent
genotype s1/m1 of vacA is clearly associated with the cagA positive genotype
(Kusters et al., 2006).  The gene dupA is associated with duodenal ulceration and has
been associated with the decreased risk for gastric atrophy and cancer (Robinson et
al., 2007).  Adhesin BabA is associated with peptic ulcers and gastric cancer (Kusters
et al., 2006), as is outer inflammatory protein OipA (Robinson et al., 2007).  SabA
might be crucial in the control of the host immune response by H. pylori (Kusters et
al., 2006). Lipopolysaccharide contains oligosaccharide antigens structurally and
immunologically closely related to human blood group antigens, and have been
suggested to promote autoantibodies and to play a role in gastric autoimmunity
(Kusters et al., 2006). However, the significance of all these virulence factors is
debatable since neither CagA nor VacA seropositivity is a better predictor of
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increased peptic ulcer or stomach cancer risk than H. pylori antibodies (González et
al., 2003, Mégraud and Lehours, 2007).
2. Epidemiology
It has been estimated that approximately 50% of the world’s population is infected
with H. pylori (Horvitz and Gold, 2006). Transmission of the infection may occur via
gastro-oral, oral-oral, and fecal-oral routes, but it is not clear which is the predominant
mode of transmission (Delport and van der Merwe, 2007, Kusters et al., 2006,
Parsonnet et al., 1999).  In general the infection is acquired during childhood
(Rehnberg-Laiho et al., 1998, Rowland et al., 2006, Malaty, 2007) and the source of
the infection is most likely the family members (Konno et al., 2005, Malaty, 2007).
The incidence of new H. pylori infections among adults in the Western world is less
than 0.5% per year (Kusters et al., 2006) and spontaneous disappearance of the
infection is rare (Kosunen et al., 1997, Malaty, 2007). The prevalence of the infection
is correlated with low socioeconomic status during childhood, high density of living,
and low household income (Malaty, 2007). The infection is steadily declining in
developed countries (Rehnberg-Laiho et al., 2001, Malaty, 2007, Kusters et al., 2006)
and its prevalence in children under the age 20 in Finland is only 5.6% (Rehnberg-
Laiho et al., 1998) as compared with 66% in Finnish centenerians (Rehnberg-Laiho et
al., 1999). This decreasing H. pylori incidence in children leads to declining
seropositivity rate in successive birth cohorts, so called cohort phenomenon.
H. PYLORI ASSOCIATED DISEASES
Since the discovery of H. pylori the associated diseases have been under intense
research. It’s now well established that only a minority of H. pylori infected persons
develop peptic ulcer or gastric cancer. The recent assumption of who develops disease
is determined largely by the inflammatory response to infection, which in turn is
determined by the virulence of the infecting strain, host genetic predisposition to
disease and environmental co-factors (Robinson et al., 2007). The negative
association with H. pylori and adenocarcinoma of the cardia has evoked concern of
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the possible detrimental effect of widespread policy of H. pylori eradication (Blaser,
1999b). There is also a hypothesis of regarding the protective effect of H. pylori
against orally ingested pathogens; and the long symbiosis between humans and H.
pylori has  evoked  an  opinion  of H. pylori being a commensal and not causing an
infection at all (Blaser, 1999b). Since atopy and autoimmunity have become more
common in developed countries as the prevalence of H. pylori has decreased, it has
been speculated that the immune response induced by H. pylori could play a general
immunoregulatory role contributing to the hygiene hypothesis (Kosunen et al., 2002,
Robinson et al., 2007).
1. H. pylori induced gastritis and atrophic gastritis
1.1. Gastritis
From the self inoculation studies it can be concluded that acute H. pylori infection in
adults is thought to be symptomatic, and to provoke acute gastritis with
polymorphonuclear infiltration in the gastric mucosa and transient hypochlorhydria
(Sobala et al., 1991, Graham et al., 2004b, Robinson et al., 2007). Since the
spontaneous clearance of the infection is rare (Valle et al., 1996, Kosunen et al.,
1997), the infection proceeds in most subjects to chronic gastritis. This inflammatory
response is mediated by cytokines, and the magnitude of the cytokine response is
influenced by genetic polymorphism. An individual’s ultimate clinical outcome is
dependent on the cytokine response and on the gastric acid secretion. Interleukin 1-
beta is in this context one of the most important pro-inflammatory cytokines and the
most powerful acid inhibitor known (El-Omar et al., 2000, Lochhead and El-Omar,
2007). An increase in stimulated acid production predisposes to duodenal ulceration
and decreased acid production predisposes to corpus gastritis or pangastritis which in
turn predisposes to gastric ulceration, atrophic gastritis, and gastric carcinoma
(Lochhead and El-Omar, 2007, Robinson et al., 2007). The intragastric distribution of
gastritis is thought to be dependent on host genetic factors, bacterial virulence factors
and environmental factors including age at onset of infection (Robinson et al., 2007).
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1.2. Atrophic gastritis
Atrophic gastritis is defined as loss of appropriate glands (Rugge et al., 2002). It is
often accompanied by intestinal metaplasia, which is recognized morphologically by
the presence of goblet and absorptive cells or cells resembling colonocytes or by its
mucin content depending on the type of intestinal metaplasia (Dixon et al., 1996,
Lauwers, 2003). It is estimated that about 50% of H. pylori infected persons develop
atrophic gastritis during their lifetime (Lauwers, 2003). Atrophic gastritis and
intestinal metaplasia are considered to be precancerous conditions and there is a
significant association between the extent of intestinal metaplasia, its phenotype
(intestinal, incomplete, or colonic), and increased cancer risk (Lauwers, 2003). The
cancer risk is 5 to 90-fold depending on the extent and severity of atrophy (Sipponen
and Graham, 2007).
Chronic atrophic gastritis has been classically divided into type A,
autoimmune corpus-dominated gastric atrophy, and type B H. pylori associated
multifocal atrophic gastritis affecting both antrum and corpus (Dixon et al., 1996,
Pérez-Pérez, 1997). However, the division into two entities has now been impugned
(see below). About 10 to 15% of patients with atrophic gastritis develop pernicious
anaemia (PA), which is a malabsorption of vitamin B12 leading to characteristic
anaemia. There is a clear familial tendency to develop autoimmune gastritis (Baxter et
al., 2005).
1.2.1. The role of H. pylori in autoimmune gastritis
Accumulating data suggest that gastric corpus atrophy is caused by H. pylori driven
autoimmune process (Annibale et al., 2001, Bergman et al., 2005, Oh et al., 2006a),
although the role of H. pylori as a trigger in autoimmune gastritis is debatable (Faller
et al., 1997, Pérez-Pérez, 1997, Hershko et al., 2005, Malfertheiner et al., 2007). A
substantial proportion of patients with autoimmune gastritis has or has had H. pylori
infection (Bergman et al., 2005, Annibale et al., 2007). During long follow-up,
patients with H. pylori gastritis may develop autoimmune type gastritis with elevated
parietal cell antibodies (PCA) and a normal antrum mucosa (Valle et al., 1996). In a
recent population screening study, almost all patients with pre-autoimmune type, but
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not yet atrophic, gastritis had active H. pylori infection (Storskrubb et al., 2005). With
an increase in the grade of corpus atrophy, H. pylori seropositivity declines but the
prevalence of PCA increases (Oksanen et al., 2000). In patients with atrophic corpus
gastritis the eradication of H. pylori may restore the atrophic changes and function of
the corpus mucosa (Annibale et al., 2002) the longer the follow-up period (Kokkola et
al., 2002). Thus, atrophic corpus gastritis seems not to proceed at least after
eradication therapy. Patients with positive H. pylori serology as the only marker of the
infection had a higher grade of atrophy and more often pernicious anaemia as
compared with patients with current infection detected by other methods (Kokkola et
al., 2000). Seronegative patients had the highest grade of atrophy and PA, supporting
the hypothesis that H. pylori indeed induces autoimmune gastritis but with increasing
grade of atrophy, H. pylori disappears spontaneously (Karttunen et al., 1991, Kokkola
et al., 2003) and PA is associated with a high grade of corpus atrophy (Bergman et al.,
2005). However, among type 1 diabetics and patients with juvenile autoimmune
thyroid disease, there are patients with high titres of PCA associated with gastric
autoimmunity but no signs of H. pylori infection (Segni et al., 2004, De Block et al.,
2002). These diabetics, as compared to the H. pylori infected patients with low titres
of  PCA,  had  an  association  with  different  HLA-DQ  haplotypes  (De  Block et al.,
2002, Bergman et al., 2005). Thus, at least among patients with diabetes or
autoimmune thyroid disease, atrophic gastritis induced by H. pylori and autoimmune
gastritis may be separate entities.
1.2.2. The mechanism behind H. pylori induced autoimmunity
H. pylori has been shown to induce antibodies reactive with gastric mucosa in
approximately half of the infected individuals, and gastric H+,K+-ATPase has been
identified as the single major autoantigen in chronic H. pylori gastritis  with  corpus
atrophy (Claeys et al., 1998, Bergman et al., 2005). The autoantibodies correlate with
the severity of gastritis, atrophy and apoptosis of the corpus mucosa. Possible
mechanisms for H. pylori to induce autoimmune gastritis are the presentation of self
antigens enhanced by inflammation, and the expression of epitopes structurally
similar to those of autoantigens, so called molecular mimicry (D'Elios et al., 2004). At
least 11 epitopes of human H+,K+-ATPase recognized by autoreactive T cells have
been identified (D'Elios et al., 2005).
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1.2.3. Histological assessment of gastritis and atrophy
The grade of gastritis and atrophy is assessed according to the updated Sydney
classification (Dixon et al., 1996) with the help of the visual analogue scales,
originally presented by Tuomo Karttunen (Smith and Genta, 2000). However, there is
still some interobserver variability in these assessments among pathologists. The
repeatability is poor concerning especially the estimation of chronic residual gastritis
after H. pylori eradication therapy (Tepeš et al., 1999a) and antral atrophy (Rugge et
al., 2002).  A few mononuclear  cells  are  always  present  in  the  lamina  propria  of  the
gastric mucosa but the criteria for mild chronic inflammation is fulfilled when more
than two to five lymphocytes, plasma cells and macrophages are seen per highpower
(×40 objective) microscopic field or two or three lymphocytes or plasma cells are
seen between the foveolae (Dixon et al., 1996).
1.2.4. Serum tests in assessment of atrophy and autoimmunity
Pepsinogen (PG) I and II are two immunologically distinct hydrolyzing proteinases of
the  mucosal  lining  of  the  stomach.  PG I  consists  of  five  isozymogens  and  PG II  of
two isozymogens. Both PG I and II are secreted from the chief and mucous neck cells
of fundic glands, but PG II is also found in the antral and proximal duodenal mucosa.
The predominant PG in atrophic corpus gastritis is PG II since, in parallel with the
decline of fundic glands the secretion of PG I abates, and thus the low PG I and low
PG I/II ratio are good predictors of atrophic corpus gastritis (Samloff and Taggart,
1987). These have been investigated in screening patients with increased risk for
gastric cancer (Varis et al., 2000, Yoshida et al., 2006, Palli et al., 2007, Sipponen
and Graham, 2007, Cao et al., 2007).
Gastrin is secreted by antral G cells and it regulates the gastric acid secretion.
In blood several forms of gastrin exist, the most prevalent being gastrin-34 (this
accounts for the basal secretion) and gastrin-17 (stimulated by food ingestion)
(Kaneko et al., 2002).  Low  gastrin-17  is  a  sign  of  multifocal  or  antrum-limited
atrophic gastritis in patients with H. pylori infection (Sipponen et al., 2002, Yoshida
et al., 2006). In patients with atrophic corpus gastritis including patients with PA the
serum gastrin levels are elevated (Bergman et al., 2005).
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PCA  were  discovered  in  over  90%  of  patients  with  PA  as  early  as  in  the  1960’s
(Whittingham and Mackay, 2005). Later on the autoantigen was identified as H+/K+
adenosine triphospahatase, the proton pump of the gastric glands (Bergman et al.,
2005). These antibodies are detected in some 60% of patients with atrophic gastritis.
In 50 to 70% of patients with PA there are antibodies against gastric secreted intrinsic
factor, a product of parietal cells, which enhances the absorption of vitamin B12
(Whittingham and Mackay, 2005).
1.3. Dyspepsia
Dyspepsia or indigestion has several definitions.  According to the Rome II criteria it
is defined as upper abdominal pain or discomfort (Talley et al., 1999). The prevalence
of dyspepsia in the community is about 40% during six months (Moayyedi et al.,
2006). These patients constitute a significant burden to health care. Around 60% of
them have negative investigations and are labelled as having non-ulcer or functional
dyspepsia (Moayyedi et al., 2006), which remains a poorly defined entity and its
association with H. pylori remains still unknown (Lai and Sung, 2007). In 10% of
dyspepsia patients eradication therapy leads to long term symptom improvement
according to the Cochrane review (Moayyedi et al., 2006) and in addition it reduces
the risk of long term sequelae (atrophic gastritis and gastric cancer) of H. pylori
infection (Malfertheiner et al., 2007).  Dyspepsia is an accepted indication for H.
pylori eradication (Malfertheiner et al., 2007).
2. Peptic ulcer
2.1. Epidemiology
H. pylori has apparently colonized human stomach since time immemorial (Linz et
al., 2007), but duodenal ulcer disease has been present essentially only for 200 years
(Blaser, 1998, Blaser, 1999a). The first description of gastric ulceration was made in
1506 by an Italian physician (Egan and O'Morain, 2007), but in mid nineteenth
century physicians began to observe more often peptic ulceration, initially gastric
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ulcers in young women and then duodenal ulcers in men (Blaser, 1998). The life-time
risk of peptic ulcer in a person with H. pylori infection varies from 3% (USA) to 25%
(Japan) (Suerbaum and Michetti, 2002). In Western countries duodenal ulcers are
approximately four-fold more common than gastric ulcers; elsewhere gastric ulcers
are more common (Kusters et al., 2006). It is widely accepted that the chronic active
gastritis affecting mainly the antrum is associated with duodenal ulcer disease (Dixon,
2000).
2.2. Pathogenesis
The pathogenesis of peptic ulcer disease is not thoroughly understood. The
localisation of the ulcer is determined by acid output; the higher the output, the more
distal the ulcer (Johnson, 1957, Albillos et al., 1990, Savarino et al., 1995). The acid
secretion however, varies widely in peptic ulcer patients (Savarino et al., 1995) and
benign gastric ulcers in a persistently achlorhydric stomach have been described
(Bynum, 1991). The peptic ulcer studies in animals indicate that pepsin in
combination with acid produces much more severe mucosal damage than acid alone,
but there is considerable overlap between ulcer patients and control subjects and no
pepsinogen level is diagnostic for peptic ulcer (Samloff and Taggart, 1987).  The
“leaky roof” theory, linking H. pylori and increased acid secretion, presupposes that
acid injury in the duodenum promotes the development of gastric metaplasia,
allowing the H. pylori to attach these areas and this leads to duodenal ulcer (Egan and
O'Morain, 2007). However, attachment of H. pylori to gastric apical cells indeed
induces proinflammatory chemokines and changes core protein expression leading to
changes in the mucous gel layer, but neither these alterations in mucosal protection
(Jass and Walsh, 2001) nor the studies on the host’s genetic polymorphism of
inflammatory and immunoregulatory cytokines (Blanchard et al., 2004) account for
the disease phenotype. The outcome of H. pylori gastritis on an individual basis
cannot be predicted by virulence factors of the bacteria e.g. CagA either (González et
al., 2003, Sgouros and Bergele, 2006). Venerably, we have to admit that we do not
know why some people develop peptic ulcer, but the exogenous risk factors must be
responsible for the rapid changes in the epidemiology of the disease (Kusters et al.,
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2006). In areas of high prevalence of H. pylori infection it is a challenge to identify
patients at risk of peptic ulcer.
2.3. Duodenal gastric metaplasia (DGM)
DGM indicates the presence of patches of mucus-secreting gastric-type cells along the
villous surfaces in duodenum. It is differentiated from heterotopia, supposed to be a
congenital abnormality, where the fully developed body-type gastric mucosa contains
also parietal and chief cells (Wyatt and Rathbone, 1989). In 1935 artificial defects in
the duodenal mucosa of cats were demonstrated to heal with a simple mucous
epithelium identical with gastric surface epithelium, and in 1964 DGM was first
described in a patient with suspected Zollinger-Ellison syndrome. DGM was shown to
be associated with duodenal ulcer and high acid levels already before the discovery of
H. pylori and it was suggested to be part of the healing process following tissue
damage (Patrick et al., 1974). Steer described the adherence of (at that time unknown)
bacteria to the surface of these gastric type epithelial cells and he noticed that these
bacteria were absent from the biopsies of the patients with normal gastric and
duodenal mucosa (Steer, 1984). Active duodenitis was shown to be associated when
the extension of DGM was more than 5% (Wyatt et al., 1987). DGM was commonly
found in asymptomatic volunteers and small foci were not associated with
inflammation and therefore the clinical importance of gastric metaplasia was
questioned (Fitzgibbons et al., 1988). However, at the same time it was suggested that
the gastric antrum was necessary for H. pylori colonization and the bacterial infection
in the duodenal bulb was made possible by its mucosal change. This change was
originally meant to protect the duodenal mucosa, but H. pylori infection in the bulb
predisposed to ulcerative lesions (Caselli et al., 1988).
After the strong association shown between DGM and duodenal ulcer, DGM if
colonized by H. pylori turned out to be an even stronger risk factor for duodenal ulcer
(Carrick et al., 1989). The inflammatory injury of the duodenal mucosa caused by H.
pylori was supposed to stimulate further gastric metaplasia and as part of the vicious
circle the progressively increasing area led to ulceration (Wyatt et al., 1990). Since
then several studies on the association between DGM and duodenal ulcer have been
published but the significance of DGM in duodenal ulcer pathogenesis is still
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questionable (Savarino et al., 1997, McColl, 1996, Jonkers et al., 1998). However,
many studies have shown that in patients with duodenal ulcer, the prevalence and
extension of gastric metaplasia in the duodenum are more widespread as compared to
non-ulcer dyspepsia or gastric ulcer patients (Wyatt et al., 1987, Kreuning et al.,
1989, Carrick et al., 1989, Wyatt et al., 1990, Andersen et al., 1991, Amarapurkar et
al., 1993, Yang et al., 1995, Harris et al., 1996, Pan et al., 1996, Jonkers et al., 1998,
Kim et al., 1998, Futami et al., 1999, Heikkinen et al., 2001, Chang et al., 2001).
Recently, in a prospective study positive H. pylori culture from the duodenal bulb was
a strong risk factor for subsequent development of duodenal ulcer (Pietroiusti et al.,
2005). In accordance with the association of DGM with hyperacidity, in atrophic
gastritis DGM is non-existent (Wyatt et al., 1990).  For reasons unknown, it has been
shown to be common also in H. pylori negative non-ulcer dyspepsia (Heikkinen et al.,
2001).
2.3.1. Regression of DGM
The effect of H. pylori eradication  on  the  prevalence  and  extent  of  DGM  is
contradictory (Noach et al., 1993, Harris et al., 1996, Khulusi et al., 1995, Savarino et
al., 2000, Bago et al., 2002). Healing of duodenal ulcer had no effect on the extent of
gastric metaplasia but acid suppressive therapy and H. pylori eradication diminished
the area significantly during a six month period (Khulusi et al., 1996), and a longer
follow-up of four years also showed a declining tendency (Kim et al., 1998).
The prevalence of DGM in vagotomized patients was reported to be lower than in
duodenal ulcer patients (Wyatt et al., 1987), although the 2 to 3 year follow-up of
patients after vagotomy failed to show any change either in the prevalence or in the
extent of DGM (Jönsson et al., 1988).
The mechanism behind DGM is suggested to be the high acid exposure which
impairs the function of Cdx2, considered to be the master regulator of intestinal
differentiation (Faller et al., 2004).
22
2.4. H. pylori eradication in peptic ulcer disease
Of the duodenal ulcers 95%, and of the gastric ulcers, 70% are associated with H.
pylori (Ford et al., 2006). As far as ulcer healing is concerned in duodenal ulcer
patients, H. pylori eradication is superior to ulcer healing drugs, but in gastric ulcers
there is no difference between these two therapies. In both duodenal and gastric ulcers
eradication therapy is clearly effective in preventing the recurrence of ulcers when
compared to patients with no ulcer healing drug therapy: duodenal ulcers recurred in
6%  of  patients  successfully  treated  for H. pylori compared  with  67%  of  those  who
remained positive for H. pylori,  whereas  in  gastric  ulcers  the  response  was  4% and
59%, respectively (Hopkins et al., 1996).  In duodenal ulcer patients H. pylori
eradication therapy and continuous therapy with modern ulcer healing drugs are
equally effective in preventing recurrence. In patients with gastric ulcer there are no
such studies (Ford et al., 2006).  However,  eradication  therapy  is  cost  effective  and
continuous PPI therapy is an option only for patients with contraindications for H.
pylori eradication therapy or several unsuccessful eradication therapies. Patients with
peptic ulcer disease benefit clearly from H. pylori eradication according to the recent
Cochrane Database of Systematic Reviews (Ford et al., 2006) and H. pylori
eradication is strongly recommended for these patients also in the Maastricht II and
III Consensus reports (Malfertheiner et al., 2002) (Malfertheiner et al., 2007).
2.5. Non-steroidal anti-inflammatory drugs (NSAID) and peptic ulcer
NSAIDs or H. pylori alone increase the risk of peptic ulcer about 20-fold, but H.
pylori infected NSAID users are 60 times more likely to develop a peptic ulcer than
uninfected non-NSAID users (Lai and Sung, 2007). NSAIDs and H. pylori infection
independently increase also the risk of peptic ulcer bleeding. In patients with chronic
NSAID use, PPI maintenance treatment is better than H. pylori eradication therapy in
preventing upper gastrointestinal bleeding. However, H. pylori eradication therapy is
of value in chronic NSAID and low dose aspirin users although it is insufficient to
prevent ulcer disease and bleeding completely. H. pylori eradication therapy is
recommended to all naive NSAID users and to chronic NSAID users needing PPI
therapy for NSAID related side-effects, the latter to prevent the development of
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atrophic gastritis accelerated by PPIs (Malfertheiner et al., 2007). Eradication
treatment is also recommended to patients on low-dose aspirin therapy with a history
of peptic ulcer (Lai and Sung, 2007).
2.6. Vagotomy
Highly selective vagotomy (HSV) was the surgical treatment of choice for patients
with chronic duodenal ulceration before the era of H. pylori eradication  therapy.  In
the procedure the nerves controlling the gastric emptying were preserved while those
controlling acid secretion were divided (Donahue, Griffith and Richter, 1996). The
operation decreased the peak acid output by approximately 50% (Egan and O'Morain,
2007). The rate of ulcer recurrence in a study of 500 patients who had undergone
HSV was 18.5% in 15 years (Macintyre and Millar, 1991).
3. Mucosa associated lymphoid tissue lymphoma (MALT)
Primary gastric lymphomas comprising 5% of gastric malignancies, are generally
non-Hodgkin lymphomas (NHL) and the most common histological subtypes are
diffuse large B-cell and marginal zone B-cell NHL of the MALT-type (Ferrucci and
Zucca,  2007).  In  Finland  according  to  the  statistics  of  the  Finnish  Cancer  Registry
(www.cancerregistry.fi), there were 59 NHLs of the stomach in 2003. Less than 1%
of H. pylori infected subjects develop MALT lymphoma (Kusters et al., 2006) but of
the patients with MALT lymphoma 72-98% are infected with H. pylori (Suerbaum
and Michetti, 2002). Twelve months after H. pylori eradication  therapy  62%  of
patients with low grade gastric MALT lymphoma had complete remission and thus H.
pylori eradication is first line therapy in patients in stage I disease and the indications
for eradication therapy are strong in all patients with MALT lymphoma
(Malfertheiner et al., 2007).
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4. Gastric cancer
Gastric cancer has been known since 400 BC in writings of Hippocrates (Houghton
and Wang, 2005). Environmental factors modulating the risk of gastric cancer include
certain food items and cigarette smoking (Lochhead and El-Omar, 2007).
Gastric cancer is divided according to the classification presented by Laurén into
intestinal and the diffuse type (Laurén, 1965). The incidence of gastric cancer is
declining in Western countries, especially the intestinal type of distal gastric cancer,
but  the  diffuse  type,  although  also  associated  with H. pylori, is not (Houghton and
Wang, 2005). The association of H. pylori infection with both histologic types of
gastric cancer has been equally strong (Lochhead and El-Omar, 2007) and CagA
seropositivity has been associated with gastric cancer (Held et al., 2004, Palli et al.,
2007). In most studies concerning the location of the cancer, the risk of H. pylori and
CagA seropositivity was confined to non-cardia cancer (Lochhead and El-Omar,
2007, Palli et al., 2007). Cardia cancer, formerly thought not to be associated with H.
pylori, is now divided into type A being a consequence of atrophic gastritis due to H.
pylori infection or autoimmune atrophic gastritis, and type B which resembles
oesophageal adenocarcinoma and is likely to be a consequence of short segment
gastro-oesophageal reflux disease (McColl, 2006, Palli et al., 2007). H. pylori
infection is negatively associated with gastro-oesophageal reflux disease, the reason
for this being largely unclear, but H. pylori eradication does not exacerbate symptoms
in these patients and reflux disease is not a contraindication for H. pylori eradication
(Malfertheiner et al., 2007).
The lifetime risk for gastric cancer in H. pylori infected persons is less than
2% (McColl, 2005). H. pylori has been classified as a class I carcinogen by the
International Agency for Research on Cancer 1994 (Anonymous, 1994) and it is
estimated that 60-90% of gastric cancers are associated with H. pylori (Malfertheiner
et al., 2005). In Finland the decreasing prevalence of H. pylori antibodies  has  been
associated with subsequent decreasing incidence of gastric cancer after a median
latency of 20 years (Rehnberg-Laiho et al., 2001), and this result has also been
confirmed in Japan (Kobayashi et al., 2004).
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4.1. Gastric carcinogenesis
The concept of the gastric carcinogenesis was introduced by Correa in 1988 as a
sequence of consecutive events starting from chronic superficial gastritis, atrophy and
intestinal metaplasia, dysplasia, and finally leading to gastric adenocarcinoma
(Correa, 1988). However, some recent data suggest that intestinal metaplasia is a
marker for atrophy, a paracancerous rather than precancerous condition, and that
cancer arises from a different cell lineage in gastric glands (Graham and Shiotani,
2005, Tatematsu et al., 2003, Meining et al., 2001). Histogenetically numerous
carcinomas of the stomach are primarily of the gastric type and may secondarily
change into the intestinal type (Meining et al., 2001).  In  addition,  not  all  gastric
cancers rise from atrophic gastric mucosa (Sipponen et al., 1994), although in the
totally normal stomach the cancer is extremely rare (Graham and Shiotani, 2005,
Sipponen et al., 1992).  At present gastric cancer is regarded as a paradigm for
infection-induced chronic inflammation-mediated cancer (Lochhead and El-Omar,
2007). There is experimental evidence that the origin of these cancers are bone
marrow derived stem cells (BMDC) and the role of inflammation is in creating a pro-
carcinogenic environment for engraftment of circulating marrow-derived stem cells
(Li et al., 2006, Cai et al., 2005, Houghton and Wang, 2005).  It is suggested that the
bone marrow derived cells take over the function of tissue stem cells and in the
abnormal  tissue  environment  with  lack  of  glandular  cells,  the  BMDC  fail  to
differentiate properly and progress instead to metaplasia, dysplasia, and cancer
(Houghton and Wang, 2005).
4.2. H. pylori eradication to prevent gastric cancer
After H. pylori eradication therapy acute inflammation disappears in a few weeks, but
chronic inflammation persists longer (Forbes et al., 1996, Tepeš et al., 1999b,
Franceschi et al., 2002, Hojo et al., 2002, Kuipers and Sipponen, 2006). The studies
on the resolution of atrophy and intestinal metaplasia after successful H. pylori
eradication therapy have shown variable results (Kokkola et al., 2002, Kuipers and
Sipponen, 2006, Hojo et al., 2002).
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The studies on the effect  of H. pylori eradication on gastric cancer risk have
been somewhat disappointing (Kuipers and Sipponen, 2006, Malfertheiner et al.,
2006). In some studies, H. pylori eradication has been shown to be beneficial (Saito et
al., 2000, Uemura et al., 2001, Take et al., 2005, Zhou et al., 2005, Nakagawa et al.,
2006), but in others there has been no statistical difference between treated and non-
treated (Wong et al., 2004, Leung et al., 2004, Mera et al., 2005). In a Chinese study
including patients with no precancerous conditions at baseline, no gastric cancers
were evident after eradication therapy (Wong et al., 2004).  Eradication therapy
probably does not prevent gastric cancer in subjects with precancerous conditions
(there is a point of no return) (Kuipers and Sipponen, 2006). The sustained chronic
inflammation after successful eradication as a possible explanation for dismal results
in these gastric cancer prevention studies is not thoroughly investigated.
The Maastricht III Consensus Report concluded by recommending H. pylori
eradication to prevent gastric cancer because it has the potential to reduce non cardia
gastric  cancer  risk  and  the  optimal  time  to  eradicate  is  before  the  pre-neoplastic
changes appear. Eradication is strongly indicated in patients with gastric cancer
resection, atrophic gastritis and first degree relatives of patients with gastric cancer
(Malfertheiner et al., 2007).
5. Extragastric diseases
H. pylori has been implicated in several studies as a cause of iron-deficiency anemia
regardless of the presence or absence of peptic ulcer disease (Cardenas et al., 2006). It
is often refractory to oral iron treatment but responds favourably to H. pylori
eradication (Hershko et al., 2005). Unexplained iron deficiency anemia is an
indication for H. pylori eradication (Malfertheiner et al., 2007).
Idiopathic thrombocytopenic purpura (ITP) is also an extragastric disease
associated with chronic H. pylori infection (Franceschi and Gasbarrini, 2007). In a
recent study 58% of ITP patients had H. pylori infection  and  62%  of  patients  with
successful eradication therapy showed increased platelet count (Kodama et al., 2007).
ITP is an indication for H. pylori eradication therapy according to the Maastricht III
Consensus Report (Malfertheiner et al., 2007).
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Other extragastric diseases possibly associated with H. pylori infection are
chronic ischemic heart disease and cerebrovascular disease but despite intensive
studies on the field, the results are contradictory and the benefit of eradication therapy
in these situations is controversial and not recommended for the present (Franceschi
and Gasbarrini, 2007, Goodman et al., 2006).
DIAGNOSTIC METHODS OF H. PYLORI INFECTION
The accuracy of all diagnostic tests described for the detection of H. pylori infection
below depends on the clinical situation in which they are used. Especially in settings
with a low prevalence of H. pylori infection even tests with high sensitivity and
specificity may turn out to give low positive predictive values and this should be
taken into account when these tests are used (Campbell and Machin, 1993). No single
method can be considered to be ideal for the detection of H. pylori infection
(Anonymous, 1997). On the other hand, the cost-effectiveness of the different
diagnostic strategies is based on the prevalence of the infection and on the price and
accuracy of different tests (Vakil et al., 2000).
There are several both invasive and non-invasive methods for the diagnosis of
H. pylori infection, see Table 1. The invasive methods need gastric biopsy material
taken by gastroscopy and non-invasive methods are based on serum, stool, urine, or
saliva specimens. In general, the choice between different methods is dependent on
the clinical situation and if gastroscopy is needed (age over 45 or alarming symptoms)
(Malfertheiner et al., 2002, Pikkarainen et al., 2002, Delaney et al., 2007).
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Table 1. Special charasteristics of the diagnostic tests for the detection of H. pylori
infection introduced into clinical practice.
Diagnostic method Special charasteristics
Invasive tests Gastroscopy needed
Rapid urease test Quick, cheap, reduced sensitivity if low number of bacteria
Histology Enables the assessment of gastric pathology, expensive
Culture from gastric
biopsies
High specificity, enables the testing of antimicrobial
susceptibility, needs sophisticated laboratory skills
PCR Sophisticated method, enables the testing of antimicrobial
susceptibility, detection of virulence factors, comparison of
clinical isolates
FISH Sophisticated method, enables the testing of antimicrobial
susceptibility
Non-invasive tests Gastroscopy not needed
EIA-based
quantitative antibody
tests
Accurate after validation, low cost, easy to perform, slow
decline in antibody titers after eradication, need for paired
serum samples in posteradication setting
Rapid blood-based
tests
Low accuracy
Immunoblot assay Detects antibodies to specific antigens e.g. CagA
Urea blood test Promising, not well studied
Urea breath test High accuracy, needs sophisticated laboratory equipment
Stool antigen tests Monoclonal EIA-based test accurate, in-office tests have low
accuracy, easy to perform, moderately expensive
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1. Invasive methods
1.1. Rapid urease test (RUT)
The RUT is based on the strong urease activity of H. pylori. Urea embedded in culture
media generates ammonia when broken down by H. pylori urease and thus produces
an increase in pH usually detected by a change in colour with an indicator. There are
both non-commercial and commercial RUTs available. The sensitivity and specificity
of these tests are dependent on the time elapsed between biopsy and reading of the
result, and the number of biopsies taken (in general only one antral biopsy) (van
IJzendoorn et al., 2005). The reaction time for the newer tests is shorter, up to three
hours compared with the 24 hours of older tests, without affecting their reliability
(Tseng et al., 2005, Malfertheiner et al., 1996). RUTs are considered highly accurate
with a sensitivity and specificity over 90% (van Keeken et al., 2006, Kuo et al., 2002,
Laine et al., 1996, Lin et al., 1992). Gastric bleeding causes low accuracy and up to
54% of H. pylori cases may be missed (Archimandritis et al., 2000b, Tu et al., 1999,
Gisbert and Abraira, 2006a, Güell et al., 2006, Castro-Fernandez et al., 2004, Peitz et
al., 2004, Chung et al., 2001, Griñó et al., 2001, Lee et al., 2000). The low accuracy
of the RUT in gastric bleeding is suggested to be partly due to technical reasons
(insufficient number of good quality biopsies), and due to PPI therapy and naso-
gastric lavage, but several studies seem to exclude the role of blood in the stomach as
a direct cause of false-negative results (Gisbert and Abraira, 2006a). Other clinical
situations with inferior performance of RUT include: post-surgical stomach
(Archimandritis et al., 2000a); gastric ulcer probably due to concomitant atrophic
corpus gastritis and low numbers of H. pylori in antral biopsies (Bermejo et al.,
2002); use of H2-blockers (Koch et al., 1990, Lerang et al., 1998); and PPIs (Yakoob
et al., 2005, Griñó et al., 2001). In addition to low sensitivity, hypochlorhydric
patients harbour other urease-positive bacteria in the stomach possibly leading to false
positive test results (Brandi et al.,  2006).  The  sensitivity  of  RUT is  considered  low
also in the post-eradication setting and figures as low as 71% four weeks after therapy
have been described (Laine et al., 1998b). Therefore, in clinical situations when there
is  a  low  density  of H. pylori, two  biopsies,  one  from  the  antrum  and  one  from  the
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corpus are recommended for the RUT (Bermejo et al., 2002, Gisbert and Abraira,
2006a).
1.2. Histology
Histology has long been considered the “gold standard” in H. pylori diagnosis
(Kusters et al., 2006, Mégraud and Lehours, 2007). However, the results of histology
are dependent on the experience of the pathologist (Metz et al., 1998, Maconi et al.,
1999), the number of biopsies taken (van IJzendoorn et al., 2005), the use of special
stains (Laine et al., 1997, Kassa et al., 1996) and the density of H. pylori in the gastric
mucosa (Epple et al., 1997, Testoni et al., 2002). In clinical practice, two biopsies
both from the antrum and the corpus are recommended (Dixon et al., 1996). However,
the recommendation of the updated Sydney System to take one extra biopsy, from the
incisura angularis gives very little additional information (Eriksson et al., 2005). The
need for special stains is especially emphasized in cases with a low density of H.
pylori; the specificity of hematoxylin-eosin stain is clearly lower (89%) when
compared to Giemsa and Genta stains (98%) (Laine et al., 1997) and the use of these
latter stains is strongly recommended (Dixon et al., 1996). In some studies
immunohistochemistry has been superior to the standard stains for H. pylori (Marzio
et al., 1998, Jonkers et al., 1997b, Ashton-Key et al., 1996, Mégraud and Lehours,
2007). In atrophic gastritis (Lahner et al., 2004, Kokkola et al., 2000, Testoni et al.,
2002) and remnant stomach (Matsukura et al., 2004), histology is insensitive. The
performance of histology in patients with gastrointestinal bleeding has been less
consistent  than  expected  with  sensitivity  between  70  to  86%  and  affected  by
medication, timing of endoscopy and the number of biopsies taken (often restricted to
minimum in unstable bleeding patients) (Laine et al., 2005, Castro-Fernandez et al.,
2004, Castillo-Rojas et al., 2002, Chung et al., 2001, Griñó et al., 2001). In a recent
meta-analysis,  the  pooled  sensitivity  and  specificity  of  histology  in  the  diagnosis  of
patients with bleeding peptic ulcer was 70% and 90%, respectively (Gisbert and
Abraira, 2006a). After H. pylori eradication therapy, the sensitivity of histology is
lower compared to the primary diagnosis and moreover, increasing the number of
biopsies is of limited value (Laine et al., 2000, Rollán et al., 1997). If histology is
used to confirm the cure of H. pylori infection,  the  optimal  time  to  test  is  4  weeks
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after antimicrobial therapy (de Boer, 1997). The absence of chronic antral
inflammation is a very reliable parameter to exclude H. pylori infection (Cutler et al.,
1995) and after eradication therapy, any persistent active gastritis may represent an
indirect sign of eradication failure in apparently H. pylori negative biopsy samples
(Anonymous, 1997, Mégraud and Lehours, 2007). PPI therapy with concomitant non-
acidic stomach causes both false positive and negative results on histology (Jonkers et
al., 1997a). However, although histology has its restrictions and is considered
expensive (Hahn et al., 2000), the major advantage of using it is the assessment of
morphological changes of the gastric mucosa (Dixon et al., 1996).
1.3. Culture and antimicrobial susceptibility
Culture of H. pylori from gastric biopsies is considered highly specific but tedious and
insensitive even in experienced laboratories (Grove et al., 1998, Andersen et al.,
1998, Ndip et al., 2003). The sensitivity is influenced by transport medium and time
(Pérez-Pérez, 2000, Ndip et al., 2003). However, in favourable circumstances it can
be very accurate, and sensitivity may reach up to 95%, and specificity is 100%
(Rautelin et al., 1997, Matsukura et al., 2004, Monteiro et al., 2001, Laheij et al.,
2000, Lerang et al., 1998, Thijs et al., 1996, Mégraud and Lehours, 2007). In general,
culture is indicated after one or two failed eradication regimens, and one to two
biopsies each from antrum and corpus are recommended for culture (Ndip et al.,
2003, Mégraud and Lehours, 2007).The sensitivity of culture is affected by
eradication therapy up to 8 weeks, and even more with triple than dual therapy (Laine
et al., 2000). The sensitivity of culture performed from one antral biopsy was 22%
lower in post-eradication setting when compared with sensitivity in primary diagnosis
(Laine et al., 2000). In patients with bleeding peptic ulcer the sensitivity in a recent
meta-analysis was 45%, but the specificity was high, 98% (Gisbert and Abraira,
2006a). Culture enables the possibility to study bacterial virulence factors (for
scientific purposes) and the antimicrobial susceptibility of H. pylori, a debatable
advantage in primary diagnosis (Zullo et al., 2003, Mégraud and Lehours, 2007). In
areas with low prevalence of primary resistance to antimicrobials used in eradication
therapy, culture gives little extra benefit. This is also true for geographical areas with
high metronidazole resistance when its use as first line therapy should be avoided. In
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Finland as reported in a recent study, the prevalence of metronidazole resistance of H.
pylori was high, 38% (45% in women) but clarithromycin resistance was only 2%
(Koivisto et al., 2004).
1.4. Molecular methods
The polymerase chain reaction (PCR) is an in vitro technique for exponentially
amplifying a predetermined fragment of DNA. PCR tests for H. pylori infection have
been based on several genes of H. pylori and all have shown good performance
(Brooks et al., 2004, Monteiro et al., 2001, Lage et al., 1995, Chisholm et al., 2001,
Pacheco et al., 2001, Peek et al., 1995, Andersen et al., 1998, Thijs et al., 1996, Fabre
et al., 1994). PCR has had high accuracy also when applied to formalin-fixed
paraffin-embedded specimens (Weiss et al., 1994). In patients with bleeding peptic
ulcer, the sensitivity of PCR was shown to be comparable to histology and superior to
RUT and serology (Castillo-Rojas et al., 2002). PCR-based methods also enable
identification of antimicrobial resistance to clarithromycin (Marais et al., 1999, van
Doorn et al., 2001, Oleastro et al., 2003, Chisholm et al., 2001). For scientific
purposes, it is possible to determine virulence factors like cagA, fingerprinting for
epidemiologic surveys (Schwarz et al., 1997) and to differentiate between reinfection
and recrudescence after failed eradication therapy (Jeen et al., 2001).
In situ hybridization is a method that uses labelled complementary DNA or
RNA  strands  to  localize  a  specific  DNA  or  RNA  sequence  in  a  tissue  section.
Fluorescent in situ hybridization (FISH) uses fluorescent probes. FISH is a new
method for H. pylori diagnosis (Trebesius et al., 2000, Rüssmann et al., 2001a).
Fluorescent labelled oligonucleotide probes binding to 16S rRNA of H. pylori provide
detection of single bacteria by fluorescence microscopy and probes to 23S rRNA
sequence enable to define clarithromycin resistance (Rüssmann et al., 2001a, Yilmaz
et al., 2007). The method is also applicable to paraffin-blocks (Trebesius et al., 2000,
Rüssmann et al., 2003) (Jüttner et al., 2004, Morris et al., 2005, Yilmaz et al., 2007).
The correlation of this method with histology and conventional chlaritromycin
susceptibility testing has been excellent (Trebesius et al., 2000, Rüssmann et al.,
2001b, Jüttner et al., 2004, Yilmaz and Demiray, 2007).
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2. Noninvasive methods
2.1. Blood-based tests
2.1.1. Enzyme immunoassay (EIA) for H. pylori antibodies
In EIA-based tests the antibody of interest  is  captured by an antigen (or antigens of
interest are captured by antibodies) usually on a solid-phase support. These captured
antibodies (or antigens) are detected by an enzyme-labelled antibody, which catalyzes
a color reaction when exposed to a substrate. The intensity of the color reaction
enables the quantification of the material of interest. Several commercial tests for H.
pylori antibodies are available (Wilcox et al., 1996, Meijer et al., 1997, Vaira et al.,
1998). A comparison of several commercial EIA-kits testing the same sera in several
laboratories in Europe indicated that Pyloriset EIA-G (Orion Diagnostics, Espoo,
Finland), one of the most widely used serology kits in Finland, has the best accuracy
(Feldman et al., 1995, Mégraud and Lehours, 2007). However, the wide range in
sensitivities and specificities of the commercial EIA-kits prompted local validation
and adjustment for cut-off values to ensure appropriate accuracy (Malfertheiner et al.,
2002). The differences in the performances of diagnostic kits in different geographic
regions are possibly due to the variation in antigenic properties of local H. pylori
strains and those used to prepare antigen for the test. However, the diagnostic
performance of properly evaluated serological assays is comparable to that of biopsy-
based methods and UBT (Oksanen et al., 1998, Herbrink and van Doorn, 2000). In
some clinical settings, serology can even be the best diagnostic modality. Recently,
the role of EIA serology has been reappraised especially in certain clinical situations
when other tests will give false negative results, e.g. bleeding ulcers, atrophic
gastritis, MALT lymphoma, and recent use of PPIs and antimicrobials (Malfertheiner
et al., 2007).
Patients with positive serology and both negative histology and culture are
overrepresented among patients with atrophic gastritis (Storskrubb et al., 2005), and
the seropositivity may actually represent individuals with an ongoing infection
(Kokkola et al., 1998). In patients with atrophic gastritis, H. pylori EIA  results
formerly considered false positive, probably reflect the insensitivity of other tests
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when H. pylori density is low (Kokkola et al., 1998). The performance of new
commercial EIA tests as compared with invasive tests has been excellent when
patients in older age-groups with atrophic gastritis have been excluded from the
analysis (Salomaa- Räsänen et al., 2004).
Serology is less affected by PPI and antibiotic therapy as compared with RUT,
UBT  or  histology  (Dickey et al., 1996). However, in very young children serology
has low accuracy (Kindermann et al., 2001, Kolho et al., 2002).  The disadvantage of
serology is also that it does not necessarily indicate a current infection: one year after
successful H. pylori eradication therapy antibodies decline below the cut-off level
only in 28% of patients (Lerang et al., 1998) and 37% in 4 years (Cutler et al., 1998).
In assessing the success of eradication therapy paired sera are needed (Kosunen et al.,
1992), and the fall in antibody titre by 50% in six months (Kosunen et al., 1992,
Fallone et al., 1998) or 40% in four months (Lerang et al., 1998) is considered a
marker for successful eradication therapy. Locally validated serology with paired sera
after eradication is highly accurate in confirming the cure of H. pylori infection, with
sensitivity of about 95-97% and a specificity of 95-100% after six months of
eradication therapy (Kosunen et al., 1992) (Hirschl and Rotter, 1996).
2.1.2. Near patient tests
These are mostly whole blood tests, but some require serum separation. The accuracy
of these commercial tests is considered poor with a sensitivity as low as 59% (Talley
et al., 1998) and a specificity as low as 54% (Sadowski et al., 1998) and they are not
recommended in clinical practice (Malfertheiner et al., 2007).
2.1.3. Immunoblot assay
In immunoblot or the Western blot, antigens separated by electrophoresis according to
their molecular weight and transferred onto nitrocellulose or other absorbent paper
react with specific antibodies which are then detected by a conjugate (labelled
antibody) and substrate as in EIA. In some studies the immunoblot assay has had
better  performance  when  compared  to  EIA  serology  and  it  enables  the  study  of
antibodies to specific antigens, for instance CagA (Nilsson et al., 1997, Andersen and
Espersen, 1992). The commercial kit Helicoblot 2.1 (Genelabs Diagnostics,
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Singapore, Singapore) is the most widely studied assay both among European and
Asian populations with good sensitivity for the diagnosis of H. pylori infection
(Hoang et al., 2006). Immunoblot CagA positivity has been used to assess the present
(Monteiro et al., 2001, Yamaoka et al., 1998) and past (Ekström et al., 2001) H.
pylori infection, the latter because these antibodies seem to stay elevated longer than
EIA serology (Ekström et al., 2001, Ekesbo et al., 2006). In some studies, antibodies
to CagA have been strongly associated with atrophic gastritis (Sande et al., 2001) and
with gastric cancer (Palli et al., 2007, Ekesbo et al., 2006, Rudi et al., 1997,
Vilaichone et al., 2003). There are, however, also contradictory results (Sokic-
Milutinovic et al., 2004, Schilling et al., 2000).
2.1.4. 13C-urea blood test
The 13C-urea blood test is based on the same 13C isotope  as  in  UBT but  the  isotope
ratio mass spectrometry measurement is done from blood instead of the exhalation, 30
minutes after the ingestion of 13C-urea. (Cutler and Toskes, 1999) The performance of
the test in adults when compared with UBT or RUT (up to 97%) (Cutler and Toskes,
1999, Ahmed et al., 2005) or histology (93%) (Chey et al., 1999) has been excellent.
2.2. Urea breath test (UBT)
2.2.1 Different UBT procedures
The  UBT  is  based  on  the  capacity  of H. pylori on the gastric mucosa to hydrolyse
orally administered isotope-labelled urea to produce isotopically labelled CO2 which
diffuses into the blood and is excreted by the lungs and can be measured in exhaled
air. UBT has several modifications concerning the use of the radioactive 14C (its use is
contraindicated in children and pregnant women) or non-radioactive 13C- isotope, the
dose (100-15 mg)  and the form (fluid or tablets) of the urea given, the test meal (no
test meal, citric acid, commercial special drinks, or fruit juices), measurement of the
isotope  (13C can be measured by isotope ratio mass spectrometry IRMS, non-
dispersive isotope-selective infrared spectrometry NDIRS or laser assisted ratio
analyser  LARA,  which  is  based  on  an  optogalvanic  effect),  and  the  optimisation  of
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the cut-off point after urea ingestion (affected by dose and form of the urea ingested
and the use of test meal) (Gisbert and Pajares, 2004c).
2.2.2. The clinical usage of UBT
In general, the UBT is considered highly accurate both in primary diagnosis and after
H. pylori eradication therapy with almost all protocols having a sensitivity and
specificity over 95% (Gisbert and Pajares, 2004c, Gomollón et al., 2003). Also the
commercial form 13C UBT (50 mg of urea combined with 456 mg citric acid) with
one to two tablets dosage has been studied in the primary diagnosis setting (Ohara et
al., 2004, Gatta et al., 2003, Hamlet et al., 1999, Wong et al., 2003) and in the post-
eradication setting (Gatta et al., 2003, Hamlet et al., 1999, Wong et al., 2003) with
excellent  concordance  with  invasive  tests  and  the  standard  UBT.  However,  atrophic
gastritis (Capurso et al., 2006, Lahner et al., 2004), gastric resection, fast gastric
emptying, and antimicrobials and bismuth disturb the performance of UBT (Gisbert
and Pajares, 2004c). Furthermore, PPI therapy decreases the accuracy of UBT
substantially (Mana et al., 2005, Peitz et al., 2004, Gatta et al., 2004, Manes et al.,
2001) and the effect lasts up to two weeks (Laine et al., 1998a, Graham et al., 2004a).
To be fully confident with UBT results, PPI therapy should be withdrawn two weeks
before testing, and although the effect of the H2-receptor antagonists on UBT results
is in most part remote, it would be safe to avoid them one day before testing (Gisbert
and Pajares, 2005). The antacids and sucralfate have no deleterious effect on the
performance of UBT (Murakami et al., 2003). In the oropharynx and in the
hypochlorhydric stomach there might be other bacteria than H. pylori with high
urease activity responsible for false positive UBT results (Brandi et al., 2006)
although the clinical relevance of this seems to be very limited (Gisbert and Pajares,
2004c). Actually, in case of apparently false positive UBT results the more probable
explanation is in fact the insensitivity of the reference method used (Epple et al.,
1997). The UBT has performed well in patients with upper gastrointestinal bleeding
when performed in emergency room before endoscopy (Winiarski et al., 2003).
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2.3. Stool tests
2.3.1. Stool culture
H. pylori culture of stool specimens has been reported, but it is tedious and not easily
reproducible (Thomas et al., 1992, Parsonnet et al., 1999, Ndip et al., 2003). It has
neither clinical nor scientific use.
2.3.2. Stool antigen tests
These tests are based either on monoclonal or polyclonal antibodies. The laboratory
tests  are  EIA  tests  (Apollo,  HePy-stool,  Hp  Ag,  Amplified  IDEIA  HpStAR  and
Premier Platinum HpSA) but also commercial near patient tests have been developed
(ImmunoCard STAT! HpSA, MiniLab and Simple H. pyl, also marketed by the name
Stick H. pylori). The most studied tests are the polyclonal antibody-based HpSA, the
monoclonal antibody-based HpStAR, and the immunochromatographic ImmunoCard
based on monoclonal antibodies.
HpSA test detects H. pylori antigens from stool specimens by an EIA
technique where the capture antibody adsorbed to microwells and the antibody, as a
component of the conjugate, are polyclonal. The HpStAR test is a monoclonal
antibody-based EIA. The ImmunoCard is an immunoassay based on a lateral flow
chromatography technique and monoclonal antibodies are used to detect H. pylori
antigens. It is a rapid test with results available within five minutes.
The early studies of the HpSA test both in primary diagnosis and in post-
eradication setting had inconsistent results. In a mini-review among 2879 patients in
pre-treatment setting when compared to UBT or endoscopy with biopsies the HpSA
test showed sensitivity of 93.1% and specificity of 92.8%, respectively and in a post-
treatment setting among 614 patients the figures were 87.8% and 88.4%, respectively
(Vaira and Vakil, 2001b). Another review article from that time included also studies
published in abstract form and including 4769 patients in pre-treatment and 2078
patients in post-treatment analysis with comparable results (Gisbert and Pajares,
2001).  However, despite good results as a whole, in individual studies even in pre-
treatment setting the performance varied and sensitivity ranged from 80% to 100%
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and specificity from 70% to 100% (Vaira and Vakil, 2001b). In addition, more
information of the HpSA test  especially in the post-treatment setting was demanded
(Vaira and Vakil, 2001b, Gisbert and Pajares, 2001, Parente et al., 2002). More
recently, a monoclonal antibody-based test HpStAR (also marketed under the name of
FemtoLab) became available with promising results in children with a sensitivity and
specificity of 98% and 96.7% in a pre-treatment setting and 100% and 96.9%,
respectively four weeks after eradication therapy (Makristathis et al., 2000). Soon
thereafter, two studies were published in adults one in a pre-treatment setting with a
sensitivity of 88.5% and specificity of 96.3% with no statistical difference when
compared with the polyclonal HpSA (Agha-Amiri et al., 2001), and another in a post-
treatment setting where the sensitivity of the monoclonal antibody-based test after
adjustment of the cut-off point was better than the sensitivity of the HpSA test with
equal specificity (Leodolter et al., 2002).
2.3.3. PCR of stool specimens
PCR based methods to detect H. pylori and even clarithromycin resistance have been
applied to stool specimens (Rimbara et al., 2005). The performance of the stool PCR
has been variable (Sen et al., 2005, Kabir, 2004) and considered, so far, insufficient
for clinical use (Wi?niewska et al., 2002, Watanabe et al., 1998).
2.4. Urine tests
The commercial tests to detect H. pylori antibodies in urine are based either on EIA or
rapid immunochromatographic methods. The EIA based Urinelisa test (Kabir, 2003)
has been evaluated in two European multicenter studies in children (Mégraud et al.,
2005) and in adults (Leodolter et al., 2003) with only modest results (sensitivity 63-
89%, specificity 68-97%). The performance of the immunochromatographic Rapirun
in adults showed a poor sensitivity of 82% and a specificity of 83% (Leodolter et al.,
2003). The disadvantage of both tests is that the sensitivity is even lower when frozen
urine samples are used (Adachi et al., 2002).
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2.5. Vomit and saliva
H. pylori has been cultivated from vomitus in a clinical experimental study (Parsonnet
et al., 1999). The EIA based tests for detection of H. pylori antibodies in saliva have
no current role in patient management because of less than optimal accuracy
(Malfertheiner et al., 2007, Kabir, 2003). A PCR method has been applied also to
saliva (Tiwari et al., 2005) but there has been considerable variation in the detection
rate (Kabir, 2004).
3. Diagnosis of H. pylori in special clinical situations
3.1. Bleeding peptic ulcer
H. pylori eradication almost eliminates the rebleeding risk in H. pylori infected
subjects; the risk is about 50% within the subsequent 10 years, if patients are left
untreated after an ulcer has healed (Gisbert et al., 2004a). The diagnosis of H. pylori
in  patients  with  a  bleeding  peptic  ulcer  is  challenging.  The  number  of  biopsies  that
can be taken in clinically unstable patients is limited, and the regularly used
antisecretory medication impairs the performance of invasive tests, UBT and stool
antigen tests (Gisbert and Abraira, 2006a). Accordingly, during acute bleeding the
sensitivity of RUT was shown to be 67%, histology 70% and culture 45% in a meta-
analysis (Gisbert and Abraira, 2006a) and even the combination of RUT and histology
was unreliable to rule out H. pylori infection (Güell et al., 2006, Chung et al., 2001).
UBT is sensitive if performed during the first 24 hours of admission (Winiarski et al.,
2003, Chung et al., 2001) with a sensitivity  of 93% in a meta-analysis (Gisbert and
Abraira, 2006a). PPI therapy, the standard treatment of patients presenting with upper
gastrointestinal bleeding, impairs the UBT result enormously; 92% of patients with
regular dose PPI therapy after one week (Peitz et al., 2004) and 60% of patients with
high dose PPI therapy after three days (Udd et al., 2003) had negative RUT. However,
serology has the advantage of not being affected by PPI therapy (Gisbert and Abraira,
2006a). The results of the polyclonal antibody-based stool antigen test have been
inconsistent: some studies have shown 100% sensitivity with very low specificity
(Griñó et al., 2003, van Leerdam et al., 2003) and in some studies the sensitivity has
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been very poor, 74% (Gisbert et al., 2004d). After acute bleeding the combination of
several tests and repeating them in negative cases, and with a sufficient interval after
antisecretory medications diminishes the false negative results (Güell et al., 2006,
Epple et al., 1997, Gisbert and Abraira, 2006a).
3.2. Children
In children presenting with abdominal symptoms, H. pylori-associated diseases such
as  ulcer  disease,  which  might  explain  the  symptoms,  are  uncommon  and  thus
clinically appropriate diagnostic interventions, not only focusing on H. pylori
infection, should be considered (Koletzko and Feydt-Schmidt, 2001, Jones et al.,
2005). The H. pylori screening for gastric cancer in children is warranted only in
families with a history of gastric cancer (Jones et al., 2005). The main H. pylori
associated extragastric conditions in children are iron-deficiency anaemia and short
stature (Horvitz and Gold, 2006). UBT is excellent in all age groups but false positive
test results may occur in young children (Koletzko and Feydt-Schmidt, 2001). It has
been suggested indeed that this may have led to the wrong conclusions in
epidemiological studies which reported high spontaneous clearance rates of H. pylori
during infancy (Koletzko and Feydt-Schmidt, 2001).  Also the compliance in children
less than three years of age may be a problem in UBT (Koletzko and Feydt-Schmidt,
2001). It remains to be shown if the urea blood test has less compliance problems; it
has been very accurate in children 2 to 18 years of age (Jolley and Wagner, 2007).
The sensitivity of serology based on IgG antibody detection is low in children under
the age of six years (Kolho et al., 2002, Kindermann et al., 2001) and in a study from
a developing country none of the children under the age of two infected with H. pylori
had positive serology (Casswall et al., 1999). However, the decline in IgG antibody
titre is useful in monitoring the eradication success also in children (Kolho et al.,
2002, Kato et al., 1999). The evidence of stool antigen tests, although the monoclonal
antibody-based test has performed well in recent studies in all age groups (Koletzko et
al., 2003, Kolho et al., 2006), is currently regarded insufficient, and according to the
last consensus conference of the Canadian Helicobacter Study Group in 2005 and the
multicenter European Study by the Pediatric Task Force on Helicobacter pylori
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infection, the UBT is the best non-invasive tool for H. pylori diagnosis in children
(Jones et al., 2005) (Mégraud et al., 2005).
3.3. The elderly
H. pylori diagnosis in the elderly has also some special characteristics. The diagnostic
strategies of dyspepsia necessitate a full diagnostic approach which must include
endoscopy so as not to ignore serious diseases more common in the old age. The
diagnosis is more challenging because of the high prevalence of atrophic gastritis (the
diagnostic difficulties are discussed below) and abundant use of antimicrobials (which
impairs the performance of many diagnostic tests) for commonplace infections in old
age (Salles-Montaudon et al., 2002). H. pylori diagnosis and therapy is understated in
the elderly hospitalized for peptic ulcer disease, at least in the United States (Pilotto
and Salles, 2002). In Finland also, bleeding peptic ulcers are common in elderly
women (Paimela et al., 2002) and the abundant use of NSAIDs in the elderly
(Klaukka et al., 2005) may lead to overlook the role of H. pylori.  The specificity of
serology as a diagnostic method in the elderly is confusing: as discussed above, in the
absence of a real gold standard in H. pylori diagnostics, the patients with positive
serology  alone  may  be  false  positives  or  the  serology  may  be  the  only  sensitive
method to detect H. pylori when it appears in low density (Salomaa-Räsänen et al.,
2004).
.
3.4. Atrophic gastritis
The diagnosis of H. pylori in atrophic gastritis is a challenge since all invasive and
almost all non-invasive tests have been shown to have poor sensitivity in this
connection (Ricci et al., 2007, Lahner et al., 2004, Testoni et al., 2002, Kokkola et al.,
2000).  Serology is sensitive, but has arguable specificity as it does not differentiate
between current and past infection. When patients with positive H. pylori serology as
the only marker of H. pylori infection received eradication therapy, they showed a fast
decline in IgG antibodies corresponding to the decline known to be diagnostic for
successful H. pylori eradication therapy (Kokkola et al., 1998). In severe atrophic
corpus gastritis the antibodies decline slowly also spontaneously and in almost one
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fourth of these patients the antibodies decline below the cut-off level within 10 years
(Kokkola et al., 2003). This discrepancy in positive serology is reflected in the use of
serology as a diagnostic method in the elderly: serology has excellent accuracy in the
elderly if the patients with atrophic corpus gastritis are excluded (Salomaa-Räsänen et
al., 2004). In a population with positive H. pylori serology  as  the  only  sign  of H.
pylori infection, atrophic gastritis and intestinal metaplasia are much more common
than in patients with current infection detectable by histology or culture. Negative
serology indeed can be used to exclude precancerous conditions with a high
probability in a screening situation (Storskrubb et al., 2005). Also in lymphocytic
gastritis, characterized by a marked increase in the number of intraepithelial
lymphocytes, histology has a low sensitivity in the diagnosis of H. pylori infection
although patients are usually seropositive for H. pylori (Mäkinen et al., 2003).The
need for a sensitive test to detect a still ongoing infection in atrophic gastritis is
urgent, especially if H. pylori eradication therapy in the late stages of gastric atrophy
is shown to prevent gastric cancer.
H. PYLORI ERADICATION THERAPY
According to the Maastricht III Consensus Report (Malfertheiner et al., 2007) the first
choice in H. pylori eradication  treatment  is  a  standard  dose  of  PPI  combined  with
clarithromycin 500mg bid and amoxicillin 1000mg bid or metronidazole 400 to
500mg bid for seven days. If continued for 14 days instead of seven this treatment is
12% more effective. This treatment is preferable if the level of local clarithromycin
resistance is less than 15-20%.  Metronidazole instead of amoxicillin is recommended
only if the resistance to it is less than 40%. Another first line therapy recommended is
so called quadruple therapy consisting of a standard dose of PPI combined with
tetracycline 500mg qid, metronidazole 400mg tid, and bismuth subsalicylate 120mg
qid. Antimicrobial resistance is the main factor influencing the treatment outcome
(Cavallaro et al., 2006, Mégraud and Lehours, 2007). The eradication rate following a
seven day therapy regimen with clarithromycin, amoxicillin and PPI has been 72-77%
(Cavallaro et al., 2006)  but  in  Finland  the  same  regimen  had  an  eradication  rate  of
91% (Koivisto et al., 2005).
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MUCOSAL RECOVERY AFTER H. PYLORI
ERADICATION THERAPY
After H. pylori eradication therapy the acute inflammation disappears in one month,
but chronic inflammation persists longer (Forbes et al., 1996, Tepeš et al., 1999b,
Franceschi et al., 2002, Hojo et al., 2002, Kuipers and Sipponen, 2006):  in a meta-
analysis the chronic inflammation improved in almost all studies; the observation
period in most studies, however, was one year or less (Hojo et al., 2002). In one study
with a four-year follow-up including only patients with a duodenal ulcer, the gastric
antral mucosa recovered in half of the patients to normal (defined as a total gastritis
score of 0 or 1) (Zerbib et al., 2000), and in another study among 11 duodenal ulcer
patients after four-year follow-up, the majority of patients had normal antrum and
corpus mucosa (defined as chronic inflammation grade 0) (Tepeš et al., 1999b).
However, the interobserver agreement in the assessment of the reversibility of
gastritis after eradication therapy has been poor (Tepeš et al., 1999a).
The studies on resolution of atrophy after successful H. pylori eradication
therapy have shown restitution of normal architecture of the mucosa with regression
of atrophic changes at least in some patients (Kokkola et al., 2002, Kuipers and
Sipponen, 2006, Hojo et al., 2002). In a few studies the regression of intestinal
metaplasia has been observed (Kuipers and Sipponen, 2006, Hojo et al., 2002). After
spontaneous disappearence of H. pylori with increasing gastric mucosal atrophy, the
normalization of antrum mucosa with disappearence of intestinal mucosa has been
suggested (Valle et al., 1996). However, in this long-term follow-up of 32 years
biopsies of the antrum mucosa at the beginning of the follow-up were not taken.
HOST RESPONSE TO H. PYLORI
The humoral immune system has only marginal relevance for protective immunity in
H. pylori infection. H. pylori induces a Th1-polarized response that unfortunately
does not result in clearance of the infection. H. pylori is  thought  to  manipulate  the
host immune response and inflammation (Kusters et al., 2006). The key activator of
the innate immune response is probably intracellular peptidoglycan (Kusters et al.,
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2006). H. pylori is capable of inhibiting phagocytosis by macrophages by an as-yet-
unknown mechanism. IL-10-producing T cells seem to be crucial in the control of
inflammation and they enable the bacteria to persist in gastric mucosa (Kusters et al.,
2006). Several cytokine genes have stable polymorphisms which are known to affect
the level of cytokine production in response to H. pylori infection (El-Omar, 2006,
Kusters et al., 2006). The best known of these is interleukin 1-?, a potent
proinflammatory cytokine and the most potent known inhibitor of acid secretion
(Kusters et al., 2006). These cytokine polymorphisms may contribute to the risk of
gastric adenocarcinoma, but their contribution to the risk of peptic ulceration is
conflicting (Chakravorty et al., 2006, Robinson et al., 2007). Reflecting the
importance of the innate immune response are the studies carried out in families with
a  high  incidence  of  gastric  cancer  where  the  combination  of  certain  cytokine
polymorphisms confer a 27-fold increased risk of gastric cancer for those infected
with H. pylori (Houghton and Wang, 2005).  The combination of high risk bacterial
genotypes elevated further the risk up to 87-fold (Houghton and Wang, 2005). The
modulating role of the immune response is thought to be responsible for the large
variation in the worldwide incidence rates of gastric cancer (Robinson et al., 2007).
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PRESENT STUDY
AIMS OF THE PRESENT STUDY
1. To evaluate the performance of stool antigen tests in the diagnosis of H. pylori
infection in the pre-treatment and post-treatment settings.
2. To study the association between the presence of widespread DGM and H. pylori
positive peptic ulcer.
3. To determine the persistence of chronic gastritis and elevated H. pylori antibody
levels after successful eradication and their possible association with each other
and with atrophic gastritis.
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PATIENTS
Study I
In five centres, 82 adult patients who had clinical indication for gastroscopy and who
were positive for H. pylori with a positive RUT were enrolled.  Patients with gastric
surgery or history of malignancy, severe reflux oesophagitis, and PPI or antimicrobial
therapy during the preceding 4 weeks were excluded. The age range was 24 to 79
years, median 53, and 46 patients were females. Patients were considered H. pylori
infected if they had, in addition to the RUT, positive histology or culture. All patients
received H. pylori eradication  therapy  and  the  treatment  combination  was  chosen  at
the discretion of the endoscopist.
Study II
A total of 1574 volunteers without significant abdominal complaints were collected
following a newspaper announcement and screened for H. pylori infection  with  a
rapid whole-blood antibody test (Pyloriset Screen II, Orion Diagnostica, Espoo
Finland, or Biocard Helicobacter pylori IgG, AniTech Ltd, Vantaa, Finland) and the
positive screening results were confirmed by EIA-based serology and 13C UBT.
Subjects with positive results in both of the confirmatory tests were enrolled.
Exclusion criteria included antimicrobial treatment during the previous 2 months, use
of  H2-blockers, PPIs or bismuth during the previous 2 weeks, H. pylori eradication
therapy during the previous 5 years, gastric surgery, chronic gastrointestinal diseases,
pregnancy and lactation, and contraindications to drugs comprising the H. pylori
eradication regimen (allergy to penicillin and prolonged QT-interval and anti-fungal
therapy for dermatophyte infection inhibiting the use of clarithromycin) or allergy to
fruit juices containing the probiotics used in the subsidiary study (Myllyluoma et al.,
2005). Of the 1574 subjects who were screened initially, 300 were positive for H.
pylori using the screening tests, 196 were positive in both of the confirmatory tests,
but  11  of  them  fulfilled  one  of  the  above  exclusion  criteria  and  thus,  the H. pylori
positive study population consisted of 185 subjects. From among the screened
population who were negative in the H. pylori tests, 114 subjects were invited as a
control group and of the 97 who accepted the invitation all were negative in both of
the confirmatory tests. The final study population consisted of 185 H. pylori positive
subjects, age range 25 to 71 years, median 55, and 97 H. pylori negative subjects, age
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range 23 to 64 years, median 43 years. In total, there were 186 females and 96 males.
All H. pylori positive subjects received the same eradication regimen viz: amoxicillin
1g bid, clarithromycin 500mg bid, and lanzoprazole 30mg bid for one week.
Study III
This study was retrospective and included 1241 mostly dyspeptic patients assessed by
gastroscopy and an additional 167 patients who had previously undergone HSV.
Patients with gastric malignancies were excluded. The HSV patients had been
gastroscopied previously median 14 years (range 3 to 18 years) after vagotomy to
assess the long-term efficacy of the surgical procedure. The endoscopy and
histological records were reviewed. A total of 198 patients were excluded; duodenal
biopsies were unavailable for 185 patients and 13 of the patients with vagotomy had
undergone gastric resection. Thus, the final study population consisted of 1056
dyspeptics (age range 16 to 88 years, median 52) and 154 patients with vagotomy
(age range 32 to 76 years, median 52 years).
Two duodenal bulb biopsies from two gastroscopies were available for 419 of
the 1056 dyspeptic patients (median interval of gastroscopies five months) and for
102 of the 154 HSV patients (median interval 12.6 months). The patients were
classified as H. pylori positive if they had positive H. pylori culture or serology and as
H. pylori negative if all tests (culture, histology and serology) were negative.
Study IV
Of 345 consecutive patients with a clinical indication for gastroscopy, a subpopulation
of 108 patients, who had at least one endoscopy performed earlier and successful H.
pylori eradication therapy on a known date, comprised the study population. The age
range was 28 to 87 years, median 65 years, and 83 were females. Seventy-seven of the
patients gave a blood sample.
The success of H. pylori eradication therapy that had been verified as
clinically appropriate was reviewed. In 54 patients verification had been made by 13C
UBT, in 26 by a new gastroscopy including histology, in 11 with a significantly
declining IgG antibody titre in paired sera, in three by the stool antigen test, and in six
by culture and histology, and in eight by only histology following the gastroscopy
performed in the present study.
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ETHICAL CONSIDERATIONS
The Ethics Committee of the Hospital District of Pirkanmaa approved the study I, the
Ethics  Committee  of  the  Hospital  District  of  Helsinki  and  Uusimaa  approved  the
studies II and IV, and the register-based study III was approved by the Hospital
District of Helsinki and Uusimaa. All patients in studies I, II, and IV gave their
written informed consent before the study and all studies were conducted in
accordance with the Declaration of Helsinki.
METHODS
Gastroscopy and collection of biopsies
During the gastroscopies (I and IV) the evident macroscopical pathology was
recorded and two biopsies were taken from the antrum and the corpus for histology.
In addition, in the study I, one biopsy was taken from the antrum and the corpus for
RUT, and the results were read within three hours according to the manufacturer’s
instructions (Pyloriset Urease, Orion Diagnostica, Espoo, Finland) and the positive
specimens were sent in the original test tubes for culture. In the study III, during the
original gastroscopies most patients had had two biopsies taken from the duodenal
bulb, antrum and corpus.
H. pylori culture
Gastric biopsies (I) were cultured on Brucella agar plates supplemented with 7%
horse blood and also on selective Brucella agar plates containing 1% Iso-Vitalex, 6
mg/L vancomycin, 2 mg/L amphotericin B, and 20 mg/L nalidixic acid. Plates were
incubated at 35 to 37 °C in a microaerobic atmosphere for a maximum of 12 days.
Identification of H. pylori was based on colony appearance, Gram staining, and
positive reactions for oxidase, urease, and catalase. The culture result was available
for most patients in study III.
Histology
All specimens in studies I and IV were stained with haematoxylin-eosin, Alcian blue
(pH 2.5)-periodic acid-Schiff and modified Giemsa stains and the samples were
examined by one experienced pathologist unaware of the identity of the samples. The
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assessment of gastric histology had been performed according to the updated Sydney
System (Dixon et al., 1996). The retrospective specimens in study III had been stained
with haematoxylin-eosin and Alcian blue (pH 2.5)-periodic acid-Schiff and examined
by several pathologists in the Department of Pathology of the University Hospital
(tertiary  referral  clinic).  The  assessment  of  DGM  was  graded  as  0  (no  gastric
metaplasia was evident), 1 (less than 20%), 2 (20 to 50%), and 3 (more than half of
the surface epithelium was covered with gastric epithelium). The duodenal biopsies
with an indistinct grade of metaplasia were re-reviewed by the same pathologist. Of
the biopsies available, the one with the most widespread DGM was included.
Serum tests
Serum samples  at  baseline  (I,  II,  IV)  and  after  therapy  (I,  II)  were  stored  at  -20  °C
until analysed. To detect H. pylori antibodies the paired sera were analyzed in
parallel. The measurements for both H. pylori antibodies of the immunoglobulin G
(IgG) and IgA classes were performed with an in-house EIA as described earlier and
demonstrated a sensitivity of 99% and specificity of 93% in detecting H. pylori
infection as compared to histology (Oksanen et al., 1998). H. pylori eradication
therapy was considered successful when antibody titres of at least the IgG class had
fallen  40%  or  more  from  the  pre-treatment  level  4  to  6  months  after  therapy.
Pepsinogen I and II, and fasting gastrin-17 levels (Gastropanel, Biohit PLC.
Diagnostics, Helsinki, Finland), and PCA (Varelisa, Pharmacia Diagnostics, Freiburg,
Germany) were investigated according to the manufacturers instructions. The normal
ranges used were those recommended by the manufacturers: for PG I 30-120 ?g/l; for
PG II 3-10 ?g/l; for PG I/PG II 3-20; for gastrin-17 2-10 pmol/l, and for PCA, below
10 U/ml.
UBT
UBTs  (I,  II)  were  performed  after  an  overnight  fast  either  with  Diabact  tablets
(Diabact AB, Uppsala, Sweden) (collection of breath sample 10 min after ingestion)
or liquid 75 mg urea-citric acid solution (collection of breath sample 30 min after
ingestion). Both were validated 13C-labelled UBT methods and the results were
measured either with isotope ratio mass spectrometry or with non-dispersive isotope-
selective infrared spectroscopy. The cut-off values were determined as delta over
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baseline (DOB) >2.2‰ in the tablet method and >4‰ positive and <2.5‰ negative in
the liquid method.
Stool antigen tests
The stool specimens in studies I and II were collected at baseline and at least 4 weeks
after eradication therapy. They were stored at -20 °C before analysis and were thawed
twice at most. Stool samples before and after eradication therapy were run in parallel
in all three antigen tests. All examinations were performed according to the
manufacturers’ instructions.
In the polyclonal antibody-based Premier Platinum HpSA test  (Meridian Inc,
Cincinnati,  Ohio,  USA),  the  recommended  sample  size  was  diluted  with  buffer  and
added to the micro-titre wells with a peroxidase-conjugated polyclonal antibody and
incubated for 1 hour at room temperature. After washing, substrate was added and
after further incubation of 10 min the stop solution was added. Results were read at
450 nm by spectrophotometry (Titertek Multiscan analyser, Eflab Oy, Helsinki,
Finland) and interpreted according to the manufacturer’s recommendations. An
optical density (OD) value < 0.140 was regarded as negative, 0.140-0.159 as
equivocal (grey zone), and > 0.160  as  positive.  The  grey  zone  results  were  retested
using the same stool samples stored at -20 °C. In addition, in the study I, all samples
were also examined after centrifuging the diluted stool specimens and using the
supernatant in the further analysis.
For the Amplified IDEIA HpStAR monoclonal antibody-based test
alternatively known as FemtoLab Cnx (Dako, Glostrup, Denmark) stool samples
suspended in sample diluent were centrifuged for 5 min and the supernatant plus the
monoclonal antibody solution were pipetted into the wells and incubated for 1 hour.
After four washes followed by 10 min incubation with the substrate, the reaction was
stopped. The OD values at 450 nm > 0.190 were interpreted as positive and < 0.190 as
negative.
For the ImmunoCard STAT!HpSA test (Meridian Bioscience Europe, Milan,
Italy), which is based on monoclonal antibodies and a lateral flow chromatography,
stool specimen with diluent was emulsified with an applicator stick and vortexed for
15 s and dispensed to the sample port of the test cassette. After incubation for 5 min at
room temperature, the appearance of a pink-red line in the reading window was
interpreted as a positive test result.
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Statistical analysis
The comparisons between the different patient groups in study III were analysed using
a multinomial logistic regression model. The results were expressed as odds ratios
(OR), confidence intervals (CI) and P values. The Fisher’s Exact Test was used for
categorical variables (III, IV). Two-sided P values less than 0.05 were considered
statistically significant. Data were analysed using SPSS for Windows software
version 12.0 (SPSS Inc, Chicago, IL). In study IV the decline in chronic gastritis and
elevated antibodies were assessed by the Linear-By-Linear Association Test, the
strata being the time. The comparisons between the patient groups in study IV were
analysed with the Pearson Chi-Square test. These data were analysed using StatXact 7
(Cytel Inc, MA, USA, 2006).
RESULTS
The performance of stool antigen tests (Studies I and II)
Of the stool antigen tests studied, the monoclonal antibody-based EIA test HpStAR
had the highest sensitivity, specificity, accuracy, and likelihood ratio both in primary
diagnosis and in a post-treatment setting. The results of the different stool antigen
tests at baseline and after eradication therapy investigated in studies I and II are
combined and presented in Tables 2 and 3. The statistics of the performance of these
tests before and after eradication therapy are presented in Tables 4 and 5.
In the study I, 18 patients did not submit a follow-up serum sample (five patients had
a therapy failure and received new eradication regimen before the 4 months follow-up
in the study protocol) and one patient was seronegative at baseline; the assessment of
the eradication result in these patients was based on UBT only. In study II, the results
of 182 patients were available after eradication therapy. Of the original 185 patients
who received eradication therapy, one died before the follow-up serum sample was
drawn, one interrupted the eradication therapy for severe headache suspected to be a
side-effect of the medication (this turned out to be viral meningitis), and one had
discrepant results in the confirmatory tests after eradication therapy and was thus
excluded from the analysis.
In the HpSA test, the grey zone values were re-examined using the same stool
specimens according to the manufacturer’s recommendations. Of the 628 test results,
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19 (3.0%) were within the grey zone in the initial test, but after retesting only three
remained in this category. When the HpSA test was repeated using centrifuged
supernatant for 82 patients in study I the result changed for nine (11%) patients (six at
baseline and three after eradication therapy). However, the results (at baseline a
sensitivity of 96% and after eradication therapy a sensitivity of 75% and specificity of
92%) were only marginally affected. When the data was statistically analyzed the
grey zone results, even after re-examination were considered neither true positive nor
true negative.
Table 2. The results of the three stool antigen tests in 364 patients (82 in Study I and
282 in Study II) at baseline as compared to reference methods. H. pylori positivity
was defined by RUT and culture or histology in patients studied with invasive
methods and by both serology and 13C UBT in patients not endoscopied.
H. pylori HpSA HpStAR ImmunoCard
Positive 267 Positive 2441 258 251
Negative 212 9 16
Grey zone 23
Negative 97 Negative 93 93 86
Positive 44 4 11
1One patient originally had a grey zone result
2Three patients originally had a grey zone result
3Grey zone results even in re-examination
4Three subjects originally had grey zone results
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Table 3. The results of the three stool antigen tests in 264 patients (82 in Study I and
182 in Study II) after H. pylori eradication therapy as compared with the reference
methods. The patients’ eradication success was classified according to the agreement
of both UBT and serology1.
H. pylori HpSA HpStAR ImmunoCard
Negative 232 Negative 2242 227 224
Positive 7 5 8
Grey zone 13
Positive 32 Positive 25 31 29
Negative 74 1 3
1Serology unavailable for 18 patients and one was originally seronegative at baseline
2Seven patients originally had grey zone results
3Grey zone even in re-examination
4Two patients originally had grey zone results
Table 4. The results of the three stool antigen tests in the diagnosis of H. pylori
infection of 364 patients (82 in Study I and 282 in Study II) at baseline.
Test Sensitivity Specificity PPV NPV Accuracy Likelihood
ratio
% % Pos Neg
HpSA 91.4 95.9 0.98 0.82 0.93 22.3 0.09
HpStAR 96.9 95.9 0.99 0.91 0.96 23.4 0.03
ImmunoCard 94.0 88.7 0.96 0.84 0.93 8.3 0.07
PPV = positive predictive value
NPV = negative predictive value
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Table 5. The results of the three stool antigen tests in the diagnosis of H. pylori
infection of 264 patients (82 in Study I and 182 in Study II) after eradication therapy.
Test Sensitivity Specificity PPV NPV Accuracy Likelihood
ratio
% % Pos Neg
HpSA 78.1 96.6 0.78 0.97 0.94 23.0 0.22
HpStAR 96.9 97.8 0.86 1.00 0.98 44.0 0.03
ImmunoCard 90.6 96.6 0.78 0.99 0.96 26.6 0.10
PPV = positive predictive value
NPV = negative predictive value
The prevalence of DGM (Study III)
Among  the  26  patients  who  had  an  ulcer  but  were H. pylori negative, widespread
DGM was detected in four (15%) patients and there was no association with the
location  of  the  ulcer.  The  results  of  the  remaining  1030  dyspeptic  patients  and  154
HSV patients, grouped according to the macroscopic findings in gastroscopy, H.
pylori infection  status  and  the  graded  extent  of  DGM are  presented  in  Table  6.  The
statistical associations between grade 1 DGM and macroscopic findings were not
significant (OR values between 1.44 and 3.57). The association between widespread
(grade 2 and 3) DGM and endoscopy findings is presented in Table 7. Of the 256 H.
pylori positive duodenal ulcer patients, with or without gastric ulcer, 55% had
widespread (more than 20%) DGM (Table 6). In patients with duodenal ulcer only,
the association with widespread DGM was very high, OR 42 (Table 7). In addition to
duodenal ulcer, widespread DGM was also significantly associated with H. pylori
positive distal gastric ulcer (Table 7). In vagotomy patients, widespread DGM
occurred only in 8.4% (Table 6), although 32 (21%) of them had had recurrent ulcers
after the primary operation; most recurrences had been gastric ulcers (19, of which 16
were prepyloric, and one further patient had both gastric and duodenal ulcer
recurrences). The widespread DGM was an uncommon finding in patients with H.
pylori gastritis and proximal gastric ulcer.
55
Table 6. Prevalence and extent of DGM in the duodenal bulb in 1030 patients grouped
according to the gastroscopy findings (including a history of endoscopy-verified
ulcer) and 154 patients who had had highly selective vagotomy (HSV).
DGM
Patient Group Grade 0
(%)
Grade 1
(%)
Grade 2 and 3
(%)
Duodenal ulcer, n=211 65 (30.8) 20 (9.5) 126 (59.7)
Duodenal & gastric ulcer1, n=45 22 (48.9) 8 (17.8) 15 (33.3)
Distal gastric ulcer2, n=83 51 (61.4) 12 (14.5) 20 (24.1)
Proximal gastric ulcer2, n=81 63 (77.8) 16 (19.8) 2 (2.5)3
Distal & proximal gastric ulcer2, n=17 13 (76.5) 2 (11.8) 2 (11.8)
Gastric ulcer, unknown location, n=4 2 (50.0) 2 (50.0) 0
H. pylori positive gastritis, n=248 216 (87.1) 22 (8.9) 10 (4.0)
H. pylori negative, no ulcer, n=341 260 (76.2) 56 (16.4) 25 (7.3)
After HSV, n=154(H. pylori positive
142, 92%)
123 (79.9) 18 (11.7) 13 (8.4)
All the ulcer patients were H. pylori positive. Of the biopsies available, the one with
the most widespread DGM was included
1The location of gastric ulcer was distal in 25, proximal in 15 and both proximal and
distal in 4 patients.
2Distal  gastric  ulcer  included  ulcers  at  pylorus,  prepylorus  (less  than  3  cm  from
pylorus), and antrum. Proximal gastric ulcer included ulcers in angulus, corpus, and
cardia.
3One patient had ulcerative lymphoma
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Table 7. Odds Ratios (OR), Confidence Intervals (CI) and P values in H. pylori
positive ulcer patients, H. pylori negative non-ulcer patients and HSV patients
according to the prevalence of widespread (grade 2 and 3) DGM. The group of
patients with H. pylori gastritis  and  no  ulcer  disease  was  used  as  the  reference
category.
Patient group No. patients OR (CI) P
Duodenal ulcer 126 41.87 (20.77 to 84.41) 0.001
Duodenal and gastric ulcer 15 14.73 (5.91 to 36.68) 0.001
Distal gastric ulcer1 20 8.47 (3.74 to 19.20) 0.001
Proximal gastric ulcer1 2 0.69 (0.15 to 3.21) 0.63
Distal & proximal gastric ulcer 2 3.32 (0.66 to 16.76) 0.15
H. pylori negative, no ulcer 25 2.08 (0.98-4.42) 0.06
After HSV 13 2.28 (0.97 to 5.36) 0.06
1Distal  gastric  ulcer  included  ulcers  at  pylorus,  prepylorus  (less  than  3  cm  from
pylorus), and antrum. Proximal gastric ulcer included ulcers in angulus, corpus, and
cardia.
Persistence of chronic gastric inflammation and elevated H. pylori antibodies
after successful eradication (Study IV)
None of the patients had acute inflammation in the gastric mucosa in gastroscopy
performed in the present study, median 6.4 years, range 0.1-15.4 years after
successful H. pylori eradication therapy. However, the persistence of the chronic
gastric inflammation and elevated H. pylori antibodies  of  the  IgG  class  were  quite
common findings although the prevalence of both declined with time, as shown in
Table 8. The decline in the prevalence of chronic gastritis (P<0.0001) and of the
elevated H. pylori antibodies  (P<0.001) was highly significant (Linear-By-Linear
Association Test, strata is time).
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Table 8.   Proportion of patients (n=108) with chronic inflammation in gastric mucosa
and proportion of patients (sera available n=77) with elevated H. pylori antibodies in
different time cohorts after successful H. pylori eradication therapy.
Number of patients with (%)
Time after H. pylori
eradication (years)
Chronic gastric
inflammation
Elevated H. pylori
antibodies
< 1 12/13  (92) 9/11  (82)
1- 2.9 5/10  (50) 3/3  (100)
3- 4.9 6/17  (35) 2/12  (17)
5- 9.9 12/51  (24) 14/37  (38)
>10 2/17  (12) 3/14  (21)
To assess the long term sequelae, the patients were divided into two groups
according to the time (< 5years, >5years) elapsed from successful eradication therapy.
Persistent chronic gastritis, even in those patients who had less than five years from
therapy, was mostly mild (Table 9). Five or more years after successful eradication
therapy, there was no association between chronic inflammation and elevated H.
pylori antibodies (Tables 10 and 11). The average age of patients at the time of
eradication therapy was 56 years for those with chronic gastric inflammation and 57
years for patients not showing chronic inflammation at least five years after successful
H. pylori eradication therapy.
The prevalence of atrophic corpus gastritis was rare throughout follow-up
(Table 9). One of the study patients developed corpus atrophy suggestive for the
autoimmune type. She had had no gastroscopy performed at the time of eradication
therapy and thus the time point for the atrophy development is not known. In the
assessment of serum markers of corpus atrophy, all patients with low PG I also had a
low ratio of PG I/II and they all had elevated levels of gastrin-17. Although rare,
atrophic corpus gastritis, whether assessed from histological specimens or by serum
markers was not associated with chronic inflammation or elevated H. pylori
antibodies after five years of eradication therapy, as shown in Tables 10 and 11. The
prevalence of intestinal metaplasia in antrum clearly declined with time, however, the
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proportion of patients with moderate to severe metaplasia remained the same (Table
9). Low gastrin-17 was found in four of the 32 patients with intestinal metaplasia in
antrum. After five years of eradication therapy, intestinal metaplasia in the antrum
was more common in patients with persistent chronic inflammation Table 10) and in
patients with no elevated H. pylori antibodies  (Table  11),  but  the  associations  were
not statistically significant.
Table 9. The findings in gastric histology of 108 patients presented according to the
time elapsed from successful H. pylori eradication therapy.
Time elapsed from eradication therapy
Finding < 5 y, n=40 (%) > 5 y, n=68 (%)
Chronic gastritis1 23 /40  (58) 14/68   (21)
   antrum & corpus    14/23  (61)    8/14   (57)
   antrum    8/23    (35)    5/14  (36)
   corpus    1/23    (4)    1/14   (7)
   grade 2 to 3 gastritis    4/23    (17)    1/14   (7)
Antral intestinal metaplasia2 19/40 (48) 13/68 (19)
   grade 2 to 3    7/19  (37)    5/13  (38)
Atrophic corpus gastritis 2/403 (5) 1/684  (1)
1P<0.0001, Pearson Chi-Square
2P<0.0024, Pearson Chi-Square
3In both, atrophy was of grade 1
4Atrophy was of grade 3
59
Table 10.  Histological findings in 68 patients with and without chronic inflammation
in the gastric mucosa at least five years after successful H. pylori eradication therapy;
serum markers were available for 51 patients.
Marker Chronic inflammation,
n=14 (%)
No chronic inflammation,
n=54 (%)
Chronic atrophic corpus
gastritis
1 (7) 0
Intestinal metaplasia in
antrum1
42 (29) 93 (17)
Serum markers:
    Elevated IgG antibodies    3/10  (30)     14/41 (34)
    Elevated PCA    1/10  (10)     6 /41  (15)
    Low PG I    1/10  (10)     0
1The difference is not statistically significant, Fisher’s Exact Test
2 In two patients intestinal metaplasia was of grade 1
3In six patients intestinal metaplasia was of grade 1
Table 11.   Serum and histological findings in 51 patients with and without
persistently elevated IgG antibodies five years or more after successful H. pylori
eradication therapy.
Marker Elevated IgG antibodies,
n=17 (%)
Not elevated IgG
antibodies, n=34 (%)
Elevated PCA 2 (12) 5 (15)
Low PG I 0 1 (3)
Chronic inflammation
in gastric mucosa
3 (18) 7 (21)
Atrophic corpus gastritis 0 11 (3)
Intestinal metaplasia in
antrum2
2 (12) 9 (26)
1Atrophy was of grade 3.
2The difference is not statistically significant, Fisher’s Exact Test.
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DISCUSSION
Evaluation of stool antigen tests in the diagnosis of H. pylori infection (Studies I
and II)
Stool antigen tests have been under intensive investigation and development during
the last few years. In our study, where three stool antigen tests were compared, the
monoclonal antibody-based stool antigen EIA test (HpStAR) showed the best overall
performance. Our results are in accordance with a recent meta-analysis, in which the
same test  showed a  pooled  sensitivity  of  94% and a  specificity  of  97% (our  results,
97% and 96%, respectively) in pre-treatment setting and a sensitivity of 93% and a
specificity of 96% (our results, 97% and 98%, respectively) in post-treatment setting
(Gisbert et al., 2006b). In the same meta-analysis, the polyclonal antibody-based EIA
test (HpSA) showed almost equal specificity but clearly lower sensitivity both in the
pre-treatment and post-treatment settings. Especially in the post-treatment setting, the
differences between the sensitivities of monoclonal and polyclonal antibody-based
EIA  tests  were  substantial  (sensitivities  91%  and  76%,  respectively).  This  was  also
shown in our study, as the specificities of the tests were almost equal (96% for both
tests in pre-treatment, and 98% and 97% in post-treatment setting, respectively),
whereas the sensitivities were for the monoclonal and polyclonal antibody-based tests
at baseline 97% and 92%, respectively, and in the post-treatment setting 97% and
78%, respectively (Table 4 and 5). Furthermore, the differences between positive and
negative test results obtained with the monoclonal antibody-based test are generally
greater as compared with the polyclonal antibody-based test, allowing better
distinction, reproducibility and no need for a grey zone.
In study I, at baseline, the reference methods used were invasive methods
i.e.RUT, histology and culture; and in study I, after eradication therapy and in study II
in the pre- and post-eradication settings, serology and UBT were used. This is in line
with the recommendation that two reference methods should be used when new
methods are being evaluated (Mégraud and Lehours, 2007) and also according to the
fact that biopsy-based methods show low sensitivity in the post-treatment setting
(Laine et al., 1998b, Laine et al., 2000). The different screening and confirmation
methods used in Studies I (positive RUT in screening and confirmation with histology
and serology) and II (positive whole blood serology in screening and confirmation by
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EIA serology and UBT) had insignificant impact on the performance of the stool tests
at baseline. Of the 300 H. pylori positive subjects screened in Study II, only 196 had
positive results in the both confirmatory tests.The excluded patients were mostly
positive in screening only, but 28 of them were also positive in EIA serology. These
28 UBT negative patients were not studied further with either the stool antigen tests or
by any invasive tests.
Although the experience with rapid “in-office” stool antigen tests is still
limited, including the ImmunoCard studied by us, they were assessed in a meta-
analysis which showed that the results were inferior when compared to the EIA tests
(Gisbert and Pajares, 2004b). As the results of the in-office tests are available within
10 minutes they have been suggested to be suitable for the use at the doctor’s office.
No studies, however, exist of the patients’ ability to give a stool specimen at the office
visit. In some studies, patients have shown an overall reluctance to collect stool
samples (O’Connor et al., 2002). Subsequent to the latest meta-analysis, several other
studies on the performance of the ImmunoCard test have been published with widely
varying sensitivity and specificity values (Lu et al., 2006) as well as inferior results
compared to EIA tests (Chisholm et al., 2004). Also in our study, the ImmunoCard
had only a moderate specificity (89%) when used as a primary diagnostic test,
although after  eradication  therapy  the  test  had  a  better  overall  performance  than  the
polyclonal antibody-based test.
Although not explored in our study, in some special clinical situations stool
antigen  tests  have  shown  the  same  restrictions  described  for  many  other  diagnostic
methods. The accuracy of stool antigen tests is hampered by PPI therapy to the same
magnitude as described for UBT (Gisbert and Pajares, 2004b). Despite the promising
reports of the stool antigen tests among patients with a bleeding peptic ulcer (Peitz et
al., 2003) (Gisbert et al., 2004d), none of the stool antigen tests can be recommended
to diagnose H. pylori infection in patients with upper gastrointestinal bleeding;
performance of the polyclonal antibody-based test has been controversial. Moreover,
the information on the monoclonal antibody-based test is limited (Gisbert and
Abraira, 2006a). Partial gastrectomy (Sheu et al., 2002), cirrhosis (Gisbert et al.,
2004b) and atrophic gastritis (Lahner et al., 2004) are other clinical settings when the
performance of stool antigen tests has been suboptimal. The sensitivity of the HpSA
test was only 40% in the study by Scheu and colleagues (Scheu et al., 2002) in
gastrectomy patients after eradication therapy and in the study by Lahner and
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colleagues (Lahner et al., 2004) in patients with atrophic corpus gastritis having H.
pylori positive histology and serology.
The prevalence of H. pylori infection is rapidly declining as shown in young
age groups and even in the older age groups. Due to the active treatment the number
of H. pylori positive subjects is lower than earlier (Malaty, 2007). In Finland and
other developed countries, H. pylori diagnostic  tests  are  at  present  used  in  an
environment with a low prevalence of the infection. This is also highlighted after
eradication therapy, as the eradication rates in Finnish patients may be exceptionally
high, 88% in our studies (I and II combined) and in a recent multi-centre study, 91%
(Koivisto et al., 2005). In practice this means that among 100 patients with H. pylori
prevalence of 10% (for instance H. pylori prevalence among volunteers in our study II
was 12%), a test with sensitivity and specificity of 98% will produce 10 true positive
and  2  false  positive  test  results  and  thus  one  of  six  patients  is  treated  in  vain.
Therefore, even if highly sensitive and specific diagnostic methods are used, the low
prevalence of H. pylori infection in the population increases the relative proportion of
false  positive  test  results  as  compared  to  true  positive  ones  and  warrants  the  use  of
several tests (Laheij et al., 2000).
Among the non-invasive tests, the monoclonal antibody-based stool antigen
EIA may be according to our study somewhat inferior to UBT and serology, but even
so it is a good and practical alternative in the diagnosis of H. pylori infection. In the
pre-treatment setting if endoscopy is performed, the stool antigen test is hardly
needed. However, among younger patients with no need for gastroscopy, the stool
antigen test could be used in combination with, for instance, serology to overcome the
problems caused by the low prevalence. In addition, in post-treatment settings, the
stool antigen test is an alternative to UBT.
The  use  of  DGM  in  selecting  patients  for H. pylori eradication therapy (Study
III)
Widespread DGM was a common finding in H. pylori positive patients with duodenal
(60%) or distal gastric ulcer (24%), and it was rare in patients with proximal gastric
ulcer (2.5%) and in patients with H. pylori gastritis but no ulcer (4%).The prevalence
of H. pylori infection varies widely and in many developing countries 80% of adult
population is infected (Malaty, 2007). As in such countries eradication of the infection
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in the whole population is not possible, the Maastricht III Consensus Report
(Malfertheiner et al., 2007) introduces guidelines for patient selection. Duodenal ulcer
is a generally accepted indication for eradication therapy. However, at the time of
gastroscopy, an ulcer may have healed with only minimal scar formation and the
treatment of patients with bulbar deformity does not prevent new ulcers. The risk for a
new peptic ulcer was 10% during a 10 year follow-up in patients with H. pylori
gastritis and the highest risk was in patients with antral predominant gastritis
(Sipponen et al., 1990). However, in that particular study, only 20% of patients with a
new ulcer that had developed during the follow-up would have received eradication
therapy on the basis of the scar formation seen in the initial gastroscopy. On the other
hand, antral predominant gastritis, suggested as an indication for H. pylori
eradication, occurs in half of the patients with chronic dyspepsia (Koskenpato et al.,
2002) and during a 6-7 year follow-up, patients with antral predominant gastritis did
not use more gastrointestinal medications or health services as compared to
individuals with other topographic types of gastritis (Heikkinen et al., 2004). Thus,
better diagnostic tools are needed to allocate the H. pylori eradication therapy
properly.
Although the association between DGM and duodenal ulcer is recognised, the
existence of DGM also in H. pylori negative subjects and the controversial results of
its prevalence in different entities have led to an underestimation of the significance
of DGM. As early as the late 1980’s, the presence of H. pylori in histological
specimens of the duodenal bulb was found to be a very strong risk factor for a
duodenal ulcer (RR 51), stronger than gastric metaplasia alone (RR 7.6). (Carrick et
al., 1989) Since the colonization of the duodenal bulb is more probable in association
with widespread DGM, these results are in line with our own study showing an OR of
42 for widespread DGM and duodenal ulcer. Recently, in a prospective study,
positive H. pylori culture from the duodenal bulb was shown to predict the duodenal
ulcer risk in a one-year follow-up (OR 6.29). (Pietroiusti et al., 2005) The sensitivity
of culture is, however, prone to errors, and in order to find H. pylori in the duodenal
bulb, histological specimens with special stains are needed. Instead, DGM and its
extent are easily detected in histological specimens. However, despite the high OR
values in the present study, widespread DGM only detected 55% of patients with
duodenal ulcer but even so widespread DGM could be added to to the list of
indications to eradicate H. pylori.  On  the  other  hand,  the  proportion  of  gastritis
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patients with widespread DGM but no ulcer was 4% in our study. This is an
acceptable number of patients receiving eradication therapy with no shown benefit (at
least as duodenal ulcer is concerned) if widespread DGM is used to detect patients for
treatment. Widespread DGM was rare or non-existent in patients with proximal
gastric ulcers or with atrophic gastritis, both recommended indications for eradication
therapy to prevent gastric cancer (Malfertheiner et al., 2007).
Based on previous studies (Jönsson et al., 1988) the low prevalence of
widespread DGM (8.4%) in HSV patients was an unexpected finding in our study.
Duodenal ulcer disease has been for all patients the indication for HSV and thus, it is
conceivable that at the time of the operation the patients had had a high prevalence of
widespread DGM which then vanished after operation probably in parallel with the
decline in duodenal acidity. As 92% of the HSV patients were H. pylori infected
many years after the operation, this opposes the hypothesis that DGM and duodenal
H. pylori infection with resulting inflammation (and extension of DGM in a vicious
circle) are crucial in the pathogenesis of duodenal ulceration.  If anything, this finding
supports the observation of the significance of acid output in determining the location
of the ulcer since most of the ulcer recurrences of these HSV patients had occurred in
the prepyloric area. This is also in accordance with the finding of the high acid
exposure impairing the function of Cdx2, the master regulator of intestinal
differentiation, the suggested mechanism behind the DGM (Faller et al., 2004).
The association between persistent chronic inflammation and elevated H. pylori
antibodies after successful eradication therapy (Study IV)
The persistence of chronic inflammation in the gastric mucosa (21%) and elevated H.
pylori antibodies (33%) were common findings after five years or more of successful
H. pylori eradication, both are new findings as most of former follow-up studies have
only lasted for a few years (Hojo et al. 2002). There was no association between these
two phenomena and neither of them was associated with atrophic gastritis. Five years
after eradication therapy, the persistent chronic inflammation was mild in all patients
except one. For intestinal metaplasia in the antrum, although the prevalence decreased
with time, the grade was stable. One patient developed an autoimmune type of total
gastric atrophy between two consecutive gastroscopies, however, at the time of the
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eradication therapy the gastroscopy was not performed and thus, the precise time for
the development of the atrophy can only be guessed.
Most of the studies assessing the reversibility of chronic gastritis after
eradication therapy have shown significant improvement (Hojo et al. 2002). However,
the follow-up time in these studies has been mostly one year or less. In one of these
studies with multiple biopsies taken both from the antrum and the corpus, chronic
inflammation was present in all patients after one year of successful eradication
therapy (Franceschi et al., 2002). However, studies with a longer follow-up (up to
four years) revealed conflicting results; one study showed normal antral mucosa in
only half of the patients (Zerbib et al. 2000) whereas in the other, normal antrum and
corpus mucosa was detected in the majority of the patients (Tepeš et al., 1999b).
Some of the discrepancies in the studies arise from the difficulties in the assessment
of mild chronic gastritis (Tepeš et al., 1999b). The advantage of our study is that one
experienced pathologist assessed all patient specimens unaware of the study protocol.
The possible role of the intensity of the inflammation before eradication therapy on
the persistence of the chronic inflammation after eradication has not been studied so
far.
Animal studies of experimental gastric cancer (testing the inflammatory
hypothesis) have shown that a longer duration of the infection increases the risk of
cancer, and there may be a point of no return when eradication therapy cannot
anymore prevent the cancer development (Cai et al., 2005). In our study, the average
age of the patients at the time of eradication therapy did not differ among those with
and those without chronic inflammation and therefore it is improbable that the
duration of H. pylori infection (presumably obtained in the childhood) would have
contributed to the persistence of chronic inflammation. Although we were not able to
show any association between the persistence of chronic inflammation and atrophic
gastritis, the clinical significance of the sustained inflammation in gastric
carcinogenesis remains to be shown.
Although a significant decline in H. pylori antibody titres 4 to 6 months after
eradication therapy indicates successful therapy (Kosunen et al., 1992, Lerang et al.,
1998), it may take several years before the antibodies decline below the cut-off level
(Cutler et al., 1998). The reason for the persistent positive serology is not known and
in our study it was not shown to be associated with persistent chronic inflammation
either. However, the persistent seropositivity emphasizes the importance of early
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verification of the eradication success. If later on diagnostic methods of H. pylori
infection are needed, tests capable of detecting a current infection should be used.
In our study, there was no association between persistent mostly mild chronic
gastric inflammation and elevated H. pylori antibodies and the results do not support
the hypothesis of H. pylori triggering an autoimmune process which could continue
after eradication therapy. Neither was there any association between persistently
elevated H. pylori antibodies or chronic inflammation and precancerous conditions
e.g. atrophic gastritis and intestinal metaplasia. Considering the disappointing results
of the human gastric cancer prevention studies (Wong et al., 2004), the question as to
whether sustained chronic inflammation has any role to play remains to be studied.
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CONCLUSIONS
1. Of the stool antigen tests evaluated, the monoclonal antibody-based EIA
demonstrated the best performance both in pretreatment and posttreatment settings.
This is an accurate test for the diagnosis of H. pylori infection and the performance is
comparable to other diagnostic tools. The polyclonal antibody-based EIA and the
rapid test were less accurate.
2. The presence of widespread DGM was strongly associated with a H. pylori positive
duodenal ulcer and could possibly be used to detect patients at a high risk for
duodenal ulceration for H. pylori eradication therapy.
3. Chronic gastric inflammation and elevated H. pylori antibodies persist in some
individuals, due to unknown reasons, for years after successful eradication therapy.
These phenomena are not associated with each other or with atrophic changes in the
gastric mucosa.
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